Section .0100 - Communicable Disease Control

Link to law: http://reports.oah.state.nc.us/ncac/title 10a - health and human services/chapter 41 - epidemiology health/subchapter a/subchapter a rules.html
Published: 2015

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now
CHAPTER 41 - HEALTH: EPIDEMIOLOGY

 

subchapter 41A - COMMUNICABLE DISEASE CONTROL

 

section .0100 - COMMUNICABLE DISEASE CONTROL

 

10A ncac 41a .0101       REPORTABLE DISEASES AND

CONDITIONS

(a)  The following named diseases and conditions are

declared to be dangerous to the public health and are hereby made reportable

within the time period specified after the disease or condition is reasonably

suspected to exist:

(1)           acquired immune deficiency syndrome (AIDS) ‑

24 hours;

(2)           anthrax ‑ immediately;

(3)           botulism ‑ immediately;

(4)           brucellosis ‑ 7 days;

(5)           campylobacter infection ‑ 24 hours;

(6)           chancroid ‑ 24 hours;

(7)           chikungunya virus infection - 24 hours;

(8)           chlamydial infection (laboratory confirmed)

‑ 7 days;

(9)           cholera ‑ 24 hours;

(10)         Creutzfeldt-Jakob disease – 7 days;

(11)         cryptosporidiosis – 24 hours;

(12)         cyclosporiasis – 24 hours;

(13)         dengue ‑ 7 days;

(14)         diphtheria ‑ 24 hours;

(15)         Escherichia coli, shiga toxin-producing ‑

24 hours;

(16)         ehrlichiosis – 7 days;

(17)         encephalitis, arboviral ‑ 7 days;

(18)         foodborne disease, including Clostridium

perfringens, staphylococcal, Bacillus cereus, and other and unknown causes ‑

24 hours;

(19)         gonorrhea ‑ 24 hours;

(20)         granuloma inguinale ‑ 24 hours;

(21)         Haemophilus influenzae, invasive disease ‑

24 hours;

(22)         Hantavirus infection – 7 days;

(23)         Hemolytic-uremic syndrome – 24 hours;

(24)         Hemorrhagic fever virus infection –

immediately;

(25)         hepatitis A ‑ 24 hours;

(26)         hepatitis B ‑ 24 hours;

(27)         hepatitis B carriage ‑ 7 days;

(28)         hepatitis C, acute – 7 days;

(29)         human immunodeficiency virus (HIV) infection

confirmed ‑ 24 hours;

(30)         influenza virus infection causing death – 24

hours;

(31)         legionellosis ‑ 7 days;

(32)         leprosy – 7 days;

(33)         leptospirosis ‑ 7 days;

(34)         listeriosis – 24 hours;

(35)         Lyme disease ‑ 7 days;

(36)         lymphogranuloma venereum ‑ 7 days;

(37)         malaria ‑ 7 days;

(38)         measles (rubeola) ‑ 24 hours;

(39)         meningitis, pneumococcal ‑ 7 days;

(40)         meningococcal disease ‑ 24 hours;

(41)         Middle East respiratory syndrome (MERS) - 24

hours;

(42)         monkeypox – 24 hours;

(43)         mumps ‑ 7 days;

(44)         nongonococcal urethritis ‑ 7 days;

(45)         novel influenza virus infection –

immediately;

(46)         plague ‑ immediately;

(47)         paralytic poliomyelitis ‑ 24 hours;

(48)         pelvic inflammatory disease – 7 days;

(49)         psittacosis ‑ 7 days;

(50)         Q fever ‑ 7 days;

(51)         rabies, human ‑ 24 hours;

(52)         Rocky Mountain spotted fever ‑ 7 days;

(53)         rubella ‑ 24 hours;

(54)         rubella congenital syndrome ‑ 7 days;

(55)         salmonellosis ‑ 24 hours;

(56)         severe acute respiratory syndrome (SARS) –

24 hours;

(57)         shigellosis ‑ 24 hours;

(58)         smallpox - immediately;

(59)         Staphylococcus aureus with reduced

susceptibility to vancomycin – 24 hours;

(60)         streptococcal infection, Group A, invasive

disease - 7 days;

(61)         syphilis ‑ 24 hours;

(62)         tetanus ‑ 7 days;

(63)         toxic shock syndrome ‑ 7 days;

(64)         trichinosis ‑ 7 days;

(65)         tuberculosis ‑ 24 hours;

(66)         tularemia – immediately;

(67)         typhoid ‑ 24 hours;

(68)         typhoid carriage (Salmonella typhi) ‑

7 days;

(69)         typhus, epidemic (louse-borne) ‑ 7

days;

(70)         vaccinia – 24 hours;

(71)         vibrio infection (other than cholera) – 24

hours;

(72)         whooping cough – 24 hours; and

(73)         yellow fever ‑ 7 days.

(b)  For purposes of reporting, "confirmed human

immunodeficiency virus (HIV) infection" is defined as a positive virus

culture, repeatedly reactive EIA antibody test confirmed by western blot or

indirect immunofluorescent antibody test, positive nucleic acid detection (NAT)

test, or other confirmed testing method approved by the Director of the State

Public Health Laboratory conducted on or after February

1, 1990.  In selecting additional tests for approval, the Director of the

State Public Health Laboratory shall consider whether such tests have been

approved by the federal Food and Drug Administration, recommended by the

federal Centers for Disease Control and Prevention, and endorsed by the

Association of Public Health Laboratories.

(c)  In addition to the laboratory reports for Mycobacterium

tuberculosis, Neisseria gonorrhoeae, and syphilis specified in G.S. 130A-139,

laboratories shall report:

(1)           Isolation or other specific identification

of the following organisms or their products from human clinical specimens:

(A)          Any hantavirus or hemorrhagic fever virus.

(B)          Arthropod-borne virus (any type).

(C)          Bacillus anthracis, the cause of anthrax.

(D)          Bordetella pertussis, the cause of whooping cough

(pertussis).

(E)           Borrelia burgdorferi, the cause of Lyme disease

(confirmed tests).

(F)           Brucella spp., the causes of brucellosis.

(G)          Campylobacter spp., the causes of

campylobacteriosis.

(H)          Chlamydia trachomatis, the cause of genital

chlamydial infection, conjunctivitis (adult and newborn) and pneumonia of newborns.

(I)            Clostridium botulinum, a cause of botulism.

(J)            Clostridium tetani, the cause of tetanus.

(K)          Corynebacterium diphtheriae, the cause of

diphtheria.

(L)           Coxiella burnetii, the cause of Q fever.

(M)         Cryptosporidium parvum, the cause of human cryptosporidiosis.

(N)          Cyclospora cayetanesis, the cause of cyclosporiasis.

(O)          Ehrlichia spp., the causes of ehrlichiosis.

(P)           Shiga toxin-producing Escherichia coli, a cause of

hemorrhagic colitis, hemolytic uremic syndrome, and thrombotic thrombocytopenic

purpura.

(Q)          Francisella tularensis, the cause of tularemia.

(R)          Hepatitis B virus or any component thereof, such as

hepatitis B surface antigen.

(S)           Human Immunodeficiency Virus, the cause of AIDS.

(T)           Legionella spp., the causes of legionellosis.

(U)          Leptospira spp., the causes of leptospirosis.

(V)          Listeria monocytogenes, the cause of listeriosis.

(W)         Middle East respiratory syndrome virus.

(X)          Monkeypox.

(Y)          Mycobacterium leprae, the cause of leprosy.

(Z)           Plasmodium falciparum, P. malariae, P. ovale, and

P. vivax, the causes of malaria in humans.

(AA)       Poliovirus (any), the cause of poliomyelitis. 

(BB)       Rabies virus.

CC)         Rickettsia rickettsii, the cause of Rocky Mountain

spotted fever.

(DD)       Rubella virus.

(EE)        Salmonella spp., the causes of salmonellosis.

(FF)         Shigella spp., the causes of shigellosis.

(GG)       Smallpox virus, the cause of smallpox.

(HH)       Staphylococcus aureus with reduced susceptibility to

vanomycin.

(II)          Trichinella spiralis, the cause of trichinosis.

(JJ)          Vaccinia virus.

(KK)       Vibrio spp., the causes of cholera and other

vibrioses.

(LL)        Yellow fever virus.

(MM)     Yersinia pestis, the cause of plague.

(2)           Isolation or other specific identification

of the following organisms from normally sterile human body sites:

(A)          Group A Streptococcus pyogenes (group A

streptococci).

(B)          Haemophilus influenzae, serotype b.

(C)          Neisseria meningitidis, the cause of meningococcal

disease.

(3)           Positive serologic test results, as

specified, for the following infections:

(A)          Fourfold or greater changes or equivalent changes in

serum antibody titers to:

(i)            Any arthropod-borne viruses associated with

meningitis or encephalitis in a human.

(ii)           Any hantavirus or hemorrhagic fever virus.

(iii)          Chlamydia psittaci, the cause of psittacosis.

(iv)          Coxiella burnetii, the cause of Q fever.

(v)           Dengue virus.

(vi)          Ehrlichia spp., the causes of ehrlichiosis.

(vii)         Measles (rubeola) virus.

(viii)        Mumps virus.

(ix)          Rickettsia rickettsii, the cause of Rocky

Mountain spotted fever.

(x)           Rubella virus.

(xi)          Yellow fever virus.

(B)          The presence of IgM serum antibodies to:

(i)            Chlamydia psittaci.

(ii)           Hepatitis A virus.

(iii)          Hepatitis B virus core antigen.

(iv)          Rubella virus.

(v)           Rubeola (measles) virus.

(vi)          Yellow fever virus.

(4)           Laboratory results from tests to determine

the absolute and relative counts for the T-helper (CD4) subset of lymphocytes

and all results from tests to determine HIV viral load.

 

History Note:        Authority G.S. 130A-134; 130A-135;

130A-139; 130A-141;

Amended Eff. October

1, 1994; February 1, 1990;

Temporary Amendment Eff. July

1, 1997;

Amended Eff. August

1, 1998;

Temporary Amendment Eff. February

13, 2003; October 1, 2002; February 18, 2002; June

1, 2001;

Amended Eff. April

1, 2003;

Temporary Amendment Eff. November

1, 2003; May 16, 2003;

Amended Eff. January

1, 2005; April 1, 2004;

Temporary Amendment Eff. June

1, 2006;

Amended Eff. April

1, 2008; November 1, 2007; October 1, 2006;

Temporary Amendment Eff. January

1, 2010;

Temporary Amendment Expired September 11, 2011;

Amended Eff. July 1, 2013;

Emergency Amendment Eff. September 2, 2014;

Temporary Amendment Eff. December 2, 2014;

Amended Eff. October 1, 2015.

10A NCAC 41A .0102       METHOD OF

REPORTING

(a)  When a report of a disease or condition is required to

be made pursuant to G.S. 130A‑135 through 139 and 10A NCAC 41A .0101,

with the exception of laboratories, which shall proceed as in Subparagraph (d),

the report shall be made to the local health director as follows:

(1)           For diseases and conditions required to be

reported within 24 hours, the initial report shall be made by telephone, and

the report required by Subparagraph (2) of this Paragraph shall be made within

seven days.

(2)           In addition to the requirements of

Subparagraph (1) of this Paragraph, the report shall be made on the

communicable disease report card or in an electronic format provided by the

Division of Public Health and shall include the name and address of the

patient, the name and address of the parent or guardian if the patient is a

minor, and epidemiologic information.

(3)           In addition to the requirements of

Subparagraphs (1) and (2) of this Paragraph, forms or electronic formats

provided by the Division of Public Health for collection of information

necessary for disease control and documentation of clinical and epidemiologic

information about the cases shall be completed and submitted for the following

reportable diseases and conditions identified in 10A NCAC 41A .0101(a):

(A)          acquired immune deficiency syndrome (AIDS);

(B)          brucellosis;

(C)          cholera;

(D)          cryptosporidiosis;

(E)           cyclosporiasis;

(F)           E. coli 0157:H7 infection;

(G)          ehrlichiosis;

(H)          Haemophilus influenzae, invasive disease;

(I)            Hemolytic-uremic syndrome/thrombotic

thrombocytopenic purpura;

(J)            hepatitis A;

(K)          hepatitis B;

(L)           hepatitis B carriage;

(M)         hepatitis C;

(N)          human immunodeficiency virus (HIV) confirmed;

(O)          legionellosis;

(P)           leptospirosis;

(Q)          Lyme disease;

(R)          malaria;

(S)           measles (rubeola);

(T)           meningitis, pneumococcal;

(U)          meningococcal disease;

(V)          mumps;

(W)         paralytic poliomyelitis;

(X)          psittacosis;

(Y)          Rocky Mountain spotted fever;

(Z)           rubella;

(AA)       rubella congenital syndrome;

(BB)       tetanus;

(CC)       toxic shock syndrome;

(DD)       trichinosis;

(EE)        tuberculosis;

(FF)         tularemia;

(GG)       typhoid;

(HH)       typhoid carriage (Salmonella typhi);

(II)          vibrio infection (other than cholera); and

(JJ)          whooping cough.

Communicable disease report cards, surveillance forms, and

electronic formats are available from the Division of Public Health, 1915 Mail

Service Center, Raleigh, North Carolina 27699-1915, and from local health

departments.

(b)  Notwithstanding the time frames established in 10A NCAC

41A .0101, a restaurant or other food or drink establishment shall report all

outbreaks or suspected outbreaks of foodborne illness in its customers or

employees and all suspected cases of foodborne disease or foodborne condition

in food‑handlers at the establishment by telephone to the local health

department within 24 hours in accordance with Subparagraph (a)(1) of this

Rule.  However, the establishment is not required to submit a report card or

surveillance form pursuant to Subparagraph (a)(2) of this Rule.

(c)  For the purposes of reporting by restaurants and other

food or drink establishments pursuant to G.S.130A‑138, the following

diseases and conditions listed in 10A NCAC 41A .0101(a) shall be reported:

(1)           anthrax;

(2)           botulism;

(3)           brucellosis;

(4)           campylobacter infection;

(5)           cholera;

(6)           cryptosporidiosis;

(7)           cyclosporiasis;

(8)           E. coli 0157:H7 infection;

(9)           hepatitis A;

(10)         salmonellosis;

(11)         shigellosis;

(12)         streptococcal infection, Group A, invasive

disease;

(13)         trichinosis;

(14)         tularemia;

(15)         typhoid;

(16)         typhoid carriage (Salmonella typhi); and

(17)         vibrio infection (other than cholera). 

(d)  Laboratories required to report test results pursuant

to G.S. 130A‑139 and 10A NCAC 41A .0101(c) shall report as follows:

(1)           The results of the specified tests for

syphilis, chlamydia and gonorrhea shall be reported to the local health

department by the first and fifteenth of each month.  Reports of the results of

the specified tests for gonorrhea, chlamydia and syphilis shall include the

specimen collection date, the patient's age, race, and sex, and the submitting

physician's name, address, and telephone numbers.

(2)           Positive darkfield examinations for

syphilis, all reactive prenatal and delivery STS titers, all reactive STS

titers on infants less than one year old and STS titers of 1:8 and above shall

be reported within 24 hours by telephone to the HIV/STD Prevention and Care

Branch at (919) 733‑7301, or the HIV/STD Prevention and Care Branch

Regional Office where the laboratory is located.

(3)           With the exception of positive laboratory

tests for human immunodeficiency virus, positive laboratory tests as defined in

G.S. 130A-139(1) and 10A NCAC 41A .0101(c) shall be reported to the Division of

Public Health electronically, by mail, by secure telefax or by telephone within

the time periods specified for each reportable disease or condition in 10A NCAC

41A .0101(a). Confirmed positive laboratory tests for human immunodeficiency

virus as defined in 10A NCAC 41A .0101(b) and for CD4 results defined in 10A NCAC

41A .0101(c)(4) shall be reported to the HIV/STD Prevention and Care Branch

within 24 hours of obtaining reportable test results.  Reports shall include as

much of the following information as the laboratory possesses:

(A)          the specific name of the test performed;

(B)          the source of the specimen;

(C)          the collection date(s);

(D)          the patient's name, age, race, sex, address, and

county; and

(E)           the submitting physician's name, address, and

telephone number.

 

History Note:        Authority G.S. 130A‑134; 130A‑135;

130A‑138; 130A‑139; 130A‑141;

Temporary Rule Eff. February

1, 1988, for a period of 180 days to expire on July

29, 1988;

Eff. March 1, 1988;

Amended Eff. October

1, 1994; February 3, 1992; December 1, 1991; May

1, 1991;

Temporary Amendment Eff. December

16, 1994, for a period of 180 days or until the permanent rule becomes

effective, whichever is sooner;

Temporary Amendment Expired June

16, 1995;

Amended Eff. December 1, 2007; November 1, 2007; August

1, 2005, April 1, 2003; August 1, 1998.

 

10A NCAC 41A .0103       DUTIES OF LOCAL HEALTH DIRECTOR: REPORT

COMMUNICABLE DISEASES

(a)  Upon receipt of a report of a communicable disease or

condition pursuant to 10A NCAC 41A .0101, the local health director shall:

(1)           immediately investigate the circumstances

surrounding the occurrence of the disease or condition to determine the

authenticity of the report and the identity of all persons for whom control

measures are required.  This investigation shall include the collection and

submission for laboratory examination of specimens necessary to assist in the

diagnosis and indicate the duration of control measures;

(2)           determine what control measures have been

given and ensure that proper control measures as provided in 10A NCAC 41A .0201

have been given and are being complied with;

(3)           forward the report as follows:

(A)          The local health director shall forward all

authenticated reports made pursuant to G.S. 130A‑135 to 137 of syphilis,

chancroid, granuloma inguinale, and lymphogranuloma venereum within seven days

to the regional office of the Division of Public Health.  In addition, the

local health director shall telephone reports of all cases of primary,

secondary, and early latent (under one year's duration) syphilis to the

regional office of the HIV/STD Prevention and Care Branch within 24 hours of

diagnosis at the health department or report by a physician.

(B)          The local health director shall telephone all

laboratory reports of reactive syphilis serologies to the regional office of

the Division of Public Health within 24 hours of receipt if the person tested

is pregnant.  This shall also be done for all other persons tested unless the

dilution is less than 1:8 and the person is known to be over 25 years of age or

has been previously treated.  In addition, the written reports shall be sent to

the regional office of the Division of Public Health within seven days.

(C)          Except as provided in (a)(3)(A) and (B) of this

Rule, a local health director who receives a report pursuant to 10A NCAC 41A

.0102 regarding a person residing in that jurisdiction shall forward the

authenticated report to the Division of Public Health within seven days.

(D)          Except as provided in (a)(3)(A) and (B) of this

Rule, a local health director who receives a report pursuant to 10A NCAC 41A

.0102 regarding a person who resides in another jurisdiction in North Carolina

shall forward the report to the local health director of that jurisdiction

within 24 hours.  A duplicate report card marked "copy" shall be

forwarded to the Division of Epidemiology within seven days.

(E)           A local health director who receives a report

pursuant to 10A NCAC 41A .0102 regarding a person who resided outside of North

Carolina at the time of onset of the illness shall forward the report to the

Division of Public Health within 24 hours.

(b)  If an outbreak exists, the local health director shall

submit to the Division of Public Health within 30 days a written report of the

investigation, its findings, and the actions taken to control the outbreak and

prevent a recurrence.

(c)  Whenever an outbreak of a disease or condition occurs

which is not required to be reported by 10A NCAC 41A .0101 but which represents

a significant threat to the public health, the local health director shall give

appropriate control measures consistent with 10A NCAC 41A .0200, and inform the

Division of Public Health of the circumstances of the outbreak within seven

days.

 

History Note:        Authority G.S. 130A‑141; 130A‑144;

Temporary Rule Eff. February 1, 1988, for a period of 180

days to expire on July 29, 1988;

Eff. March 1, 1988;

Amended Eff. April 1, 2003; December 1, 1991; September

1, 1990.

 

10A NCAC 41A .0104       RELEASE OF COMMUNICABLE DISEASE RECORDS:

RESEARCH PURPOSES

(a)  A person may request, for bona fide research purposes,

the release of records which pertain to a communicable disease or communicable

condition and which identify individuals.  The request shall be in writing and

shall contain the following information:

(1)           Name of organization requesting the data;

(2)           Names of principal investigators;

(3)           Name of project;

(4)           Purpose of project;

(5)           Description of the proposed use of the

data, including protocols for contacting patients, relatives, and service

providers;

(6)           Descriptions of measures to protect the

security of the data;

(7)           An assurance that the data will not be used

for purposes other than those described in the protocol;

(8)           An assurance that the data will be properly

disposed of upon completion of the project; and

(9)           An assurance that the results of the

project will be provided to the custodian of the records.

(b)  The request for release of the records shall be granted

or denied in writing based upon the following considerations:

(1)           Whether the objectives of the project

require patient identifying information;

(2)           Whether the objective of the project can be

reached with the use of the data;

(3)           Whether the project has a reasonable chance

of answering a legitimate research question;

(4)           Whether the project might jeopardize the

ability of the Epidemiology Division to obtain reports and information

regarding communicable diseases and communicable conditions;

(5)           Whether the patient's right to privacy

would be adequately protected.

 

History Note:        Temporary Rule Eff. February

1, 1988, for a period of 180 days to expire on July

29, 1988;

Authority G.S. 130A‑143(9);

Eff. March 1, 1988;

Amended Eff. September 1, 1991.

 

10a ncac 41a .0105       Hospital Emergency Department Data

Reporting

Hospitals, as defined in G.S. 130A-480(d), shall submit

electronically to the Division of Public Health the following electronically

available emergency department data elements for all emergency department

visits:

(1)           Patient record number or other unique

identification number;

(2)           Patient date of birth and age;

(3)           Patient's sex;

(4)           City of residence;

(5)           County of residence;

(6)           Five digit ZIP code;

(7)           Alpha numeric patient control number assigned by

the hospital for each record (the Visit Identification Number);

(8)           Emergency department facility identification

number;

(9)           Projected payor source;

(10)         Date and time of emergency department visit (first

documented time);

(11)         Mode of transport to the emergency department;

(12)         PreMIS identification number, if transported by EMS;

(13)         Chief complaint;

(14)         Initial temperature reading and route;

(15)         Initial systolic and initial diastolic blood

pressure;

(16)         Triage Notes (brief description of patient's/family's

self-reported illness episode, including symptoms, duration of symptoms, and

reasons for visit [in addition to Chief Complaint] as presented by the patient

or family to the triage nurse upon arrival at the emergency department) – this

element is optional;

(17)         Initial emergency department acuity assessment;

(18)         Coded cause of injury (ICD-9-CM, if injury related

to diagnosis);

(19)         Emergency department procedures, up to ten (CPT or

ICD-9-CM or ICD-10-CM);

(20)         Emergency department disposition;

(21)         Emergency department disposition diagnosis

description; and

(22)         Emergency department disposition diagnosis codes,

one primary and up to ten additional (ICD-9-CM or ICD-10-CM).

 

History Note:        Authority G.S. 130A-480;

Eff. January 1, 2005.

 

10A NCAC 41A .0106       Reporting of Health Care-Associated

Infections

(a)  The following definitions apply throughout this Rule:

(1)           "Hospital" means any facility

designated as such in G.S. 131E-76(3).

(2)           "National Healthcare Safety Network"

is an internet-based surveillance system managed by the Centers for Disease

Control and Prevention. This system is designed to be used for the direct,

standardized reporting of healthcare quality information, including health

care-associated infections, by health care facilities to public health

entities.

(3)           "Health care-associated infection"

means a localized or systemic condition in the patient resulting from an

adverse reaction to the presence of an infectious agent(s) or its toxin(s) with

no evidence that the infection was present or incubating when the patient was

admitted to the health care setting.

(4)           "Denominator or summary data"

refers to referent or baseline data required to generate meaningful statistics

for communicating health care-associated infection rates.

(5)           "The Centers for Medicaid and Medicare

Services - Inpatient Prospective Payment System (CMS – IPPS) rules" are

regulations promulgated for the disbursement of operating costs by the Centers

for Medicare and Medicaid Services for acute care hospital stays under Medicare

Part A based on prospectively set rates for care.

(b)  Hospitals shall electronically report all health

care-associated infections required by Paragraph (c) of this Rule through the

National Healthcare Safety Network and shall make the data available to the

Department.  Hospitals also shall:

(1)           Report all specified health care-associated

infections within 30 days following the end of every calendar month during

which the infection was identified;

(2)           Report all required health care-associated

infection denominator or summary data for healthcare-associated infections

within 30 days following the end of every calendar month; and,

(3)           Comply with all reporting requirements for

general participation in the National Healthcare Safety Network.

(c)  Except as provided in rules of this Section, hospitals

shall report the healthcare-associated infections required by the Centers for

Medicare and Medicaid Services listed in the CMS-IPPS rules beginning on the

dates specified therein.  A summary of the HAI reporting requirements from the current

copy of the CMS-IPPS rules may be obtained through the CMS QualityNet site at

http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier2&cid=1228760487021



The CMS IPPS rules themselves can be obtained from the CMS

IPPS website at http://www.cms.gov/AcuteInpatientPPS/IPPS2011/list.asp#TopOfPage

 and



http://www.cms.gov/AcuteInpatientPPS/FR2012/list.asp#TopOfPage.

A copy of the current CMS-IPPS rules, applicable to this section, is available

for inspection in the Division of Public Health, 225 N. McDowell Street, Raleigh

NC 27601.

(d)  Beginning October 1, 2012 and quarterly thereafter, the

Department shall release reports to the public on health care-associated

infection(s) in North Carolina.

 

History Note:        Authority G.S. 130A‑150;

Temporary Adoption Eff. November 30, 2011;

Eff. October 1, 2012.

 

CHAPTER 41 – HEALTH: EPIDEMIOLOGY

 

subchapter 41A – communicable disease control

 

section .0200 - CONTROL MEASURES FOR COMMUNICABLE DISEASES

 

10A NCAC 41A .0201       CONTROL MEASURES - GENERAL

(a)  Except as provided in Rules of this Section, the

recommendations and guidelines for testing, diagnosis, treatment, follow-up,

and prevention of transmission for each disease and condition specified by the

American Public Health Association in its publication, Control of Communicable

Diseases Manual shall be the required control measures. Control of Communicable

Diseases Manual is hereby incorporated by reference including subsequent

amendments and editions.  Guidelines and recommended actions published by the

Centers for Disease Control and Prevention shall supercede those contained in

the Control of Communicable Disease Manual and are likewise incorporated by

reference, including subsequent amendments and editions.  Copies of the Control

of Communicable Diseases Manual may be purchased from the American Public

Health Association, Publication Sales Department, Post Office Box 753, Waldora,

MD 20604 for a cost of twenty-two dollars ($22.00) each plus five dollars

($5.00) shipping and handling.  Copies of Centers for Disease Control and

Prevention guidelines contained in the Morbidity and Mortality Weekly Report

may be purchased from the Superintendent of Documents, U.S. Government Printing

Office, Washington, DC 20402 for a total cost of three dollars and fifty cents

($3.50) each.  Copies of both publications are available for inspection in the

Division of Public Health, 1915 Mail Service Center, Raleigh, North Carolina 27699-1915.



(b)  In interpreting and implementing the specific control

measures adopted in Paragraph (a) of this Rule, and in devising control

measures for outbreaks designated by the State Health Director and for

communicable diseases and conditions for which a specific control measure is

not provided by this Rule, the following principles shall be used:

(1)           control measures shall be those which can

reasonably be expected to decrease the risk of transmission and which are

consistent with recent scientific and public health information;

(2)           for diseases or conditions transmitted by

the airborne route, the control measures shall require physical isolation for

the duration of infectivity;

(3)           for diseases or conditions transmitted by

the fecal-oral route, the control measures shall require exclusions from

situations in which transmission can be reasonably expected to occur, such as

work as a paid or voluntary food handler or attendance or work in a day care

center for the duration of infectivity;

(4)           for diseases or conditions transmitted by

sexual or the blood-borne route, control measures shall require prohibition of

donation of blood, tissue, organs, or semen, needle-sharing, and sexual contact

in a manner likely to result in transmission for the duration of infectivity.

(c)  Persons with congenital rubella syndrome, tuberculosis,

and carriers of Salmonella typhi and hepatitis B who change residence to a

different local health department jurisdiction shall notify the local health

director in both jurisdictions. 

(d)  Isolation and quarantine orders for communicable

diseases and communicable conditions for which control measures have been

established shall require compliance with applicable control measures and shall

state penalties for failure to comply.  These isolation and quarantine orders

may be no more restrictive than the applicable control measures. 

(e)  An individual enrolled in an epidemiologic or clinical

study shall not be required to meet the provisions of 10A NCAC 41A .0201 -

.0209 which conflict with the study protocol if:

(1)           the protocol is approved for this purpose

by the State Health Director because of the scientific and public health value

of the study, and

(2)           the individual fully participates in and

completes the study.

(f)  A determination of significant risk of transmission

under this Subchapter shall be made only after consideration of the following

factors, if known:

(1)           The type of body fluid or tissue;

(2)           The volume of body fluid or tissue;

(3)           The concentration of pathogen;

(4)           The virulence of the pathogen; and

(5)           The type of exposure, ranging from intact

skin to non-intact skin, or mucous membrane.

(g)  The term "household contacts" as used in this

Subchapter means any person residing in the same domicile as the infected

person.

 

History Note:        Authority G.S. 130A-135; 130A-144;

Temporary Rule Eff. February 1, 1988, for a period of 180

days to expire on July 29, 1988;

Eff. March 1, 1988;

Amended Eff. February 1, 1990; November 1, 1989; August

1, 1988;

Recodified Paragraphs (d), (e) to Rule .0202; Paragraph

(i) to Rule .0203 Eff. June 11, 1991;

Amended Eff. April 1, 2003; October 1, 1992; December 1,

1991; August 1, 1998;

Emergency Amendment Eff. January 24, 2005;

Emergency Amendment Expired on April 16, 2005.

 

10A NCAC 41A .0202       CONTROL MEASURES – HIV

The following are the control measures for the Acquired

Immune Deficiency Syndrome (AIDS) and Human Immunodeficiency Virus (HIV)

infection:

(1)           Infected persons shall:

(a)           refrain from sexual intercourse unless

condoms are used; exercise caution when using condoms due to possible condom

failure;

(b)           not share needles or syringes, or any other

drug-related equipment, paraphernalia, or works that may be contaminated with

blood through previous use;

(c)           not donate or sell blood, plasma, platelets,

other blood products, semen, ova, tissues, organs, or breast milk;

(d)           have a skin test for tuberculosis;

(e)           notify future sexual intercourse partners of

the infection;

(f)            if the time of initial infection is known,

notify persons who have been sexual intercourse and needle partners since the

date of infection; and,

(g)           if the date of initial infection is unknown,

notify persons who have been sexual intercourse and needle partners for the

previous year.

(2)           The attending physician shall:

(a)           give the control measures in Item (1) of

this Rule to infected patients, in accordance with 10A NCAC 41A .0210;

(b)           If the attending physician knows the

identity of the spouse of an HIV-infected patient and has not, with the consent

of the infected patient, notified and counseled the spouse, the physician shall

list the spouse on a form provided by the Division of Public Health and shall

mail the form to the Division.  The Division shall undertake to counsel the

spouse.  The attending physician's responsibility to notify exposed and

potentially exposed persons is satisfied by fulfilling the requirements of

Sub-Items (2)(a) and (b) of this Rule;

(c)           advise infected persons concerning clean-up

of blood and other body fluids;

(d)           advise infected persons concerning the risk

of perinatal transmission and transmission by breastfeeding.

(3)           The attending physician of a child who is infected

with HIV and who may pose a significant risk of transmission in the school or

day care setting because of open, oozing wounds or because of behavioral

abnormalities such as biting shall notify the local health director.  The local

health director shall consult with the attending physician and investigate the following

circumstances:

(a)           If the child is in school or scheduled for

admission and the local health director determines that there may be a significant

risk of transmission, the local health director shall consult with an

interdisciplinary committee, which shall include school personnel, a medical

expert, and the child's parent or guardian to assist in the investigation and

determination of risk. The local health director shall notify the

superintendent or private school director of the need to appoint such an

interdisciplinary committee.

(i)            If the superintendent or private school

director establishes such a committee within three days of notification, the

local health director shall consult with this committee.

(ii)           If the superintendent or private school director

does not establish such a committee within three days of notification, the

local health director shall establish such a committee.

(b)           If the child is in school or scheduled for

admission and the local health director determines, after consultation with the

committee, that a significant risk of transmission exists, the local health

director shall:

(i)            notify the parents;

(ii)           notify the committee;

(iii)          assist the committee in determining whether

an adjustment can be made to the student's school program to eliminate

significant risks of transmission;

(iv)          determine if an alternative educational

setting is necessary to protect the public health;

(v)           instruct the superintendent or private

school director concerning protective measures to be implemented in the

alternative educational setting developed by school personnel; and

(vi)          consult with the superintendent or private

school director to determine which school personnel directly involved with the

child need to be notified of the HIV infection in order to prevent transmission

and ensure that these persons are instructed regarding the necessity for

protecting confidentiality.

(c)           If the child is in day care and the local

health director determines that there is a significant risk of transmission,

the local health director shall notify the parents that the child must be

placed in an alternate child care setting that eliminates the significant risk

of transmission.

(4)           When health care workers or other persons have a

needlestick or nonsexual non-intact skin or mucous membrane exposure to blood

or body fluids that, if the source were infected with HIV, would pose a significant

risk of HIV transmission, the following shall apply:

(a)           When the source person is known:

(i)            The attending physician or occupational

health care provider responsible for the exposed person, if other than the

attending physician of the person whose blood or body fluids is the source of

the exposure, shall notify the attending physician of the source that an

exposure has occurred.  The attending physician of the source person shall

discuss the exposure with the source and, unless the source is already known to

be infected, shall test the source for HIV infection without consent unless it

reasonably appears that the test cannot be performed without endangering the

safety of the source person or the person administering the test.  If the

source person cannot be tested, an existing specimen, if one exists, shall be

tested.  The attending physician of the exposed person shall be notified of the

infection status of the source.

(ii)           The attending physician of the exposed

person shall inform the exposed person about the infection status of the

source, offer testing for HIV infection as soon as possible after exposure and

at reasonable intervals up to one year to determine whether transmission

occurred, and, if the source person was HIV infected, give the exposed person

the control measures listed in Sub-Items (1)(a) through (c) of this Rule.  The

attending physician of the exposed person shall instruct the exposed person

regarding the necessity for protecting confidentiality.

(b)           When the source person is unknown, the

attending physician of the exposed persons shall inform the exposed person of

the risk of transmission and offer testing for HIV infection as soon as

possible after exposure and at reasonable intervals up to one year to determine

whether transmission occurred.

(c)           A health care facility may release the name

of the attending physician of a source person upon request of the attending

physician of an exposed person.

(5)           The attending physician shall notify the local

health director when the physician, in good faith, has reasonable cause to

suspect a patient infected with HIV is not following or cannot follow control

measures and is thereby causing a significant risk of transmission.  Any other

person may notify the local health director when the person, in good faith, has

reasonable cause to suspect a person infected with HIV is not following control

measures and is thereby causing a significant risk of transmission.

(6)           When the local health director is notified pursuant

to Item (5) of this Rule, of a person who is mentally ill or mentally retarded,

the local health director shall confer with the attending mental health

physician or mental health authority and the physician, if any, who notified

the local health director to develop a plan to prevent transmission.

(7)           The Division of Public Health shall notify the

Director of Health Services of the North Carolina Department of Correction and

the prison facility administrator when any person confined in a state prison is

determined to be infected with HIV.  If the prison facility administrator, in

consultation with the Director of Health Services, determines that a confined

HIV infected person is not following or cannot follow prescribed control

measures, thereby presenting a significant risk of HIV transmission, the

administrator and the Director shall develop and implement jointly a plan to

prevent transmission, including making recommendations to the unit housing

classification committee.

(8)           The local health director shall ensure that the

health plan for local jails include education of jail staff and prisoners about

HIV, how it is transmitted, and how to avoid acquiring or transmitting this

infection.

(9)           Local health departments shall provide counseling

and testing for HIV infection at no charge to the patient.  Third party payors

may be billed for HIV counseling and testing when such services are provided

and the patient provides written consent.

(10)         HIV pre-test counseling is not required.  Post-test

counseling for persons infected with HIV is required, must be individualized,

and shall include referrals for medical and psychosocial services and control

measures.

(11)         A local health department or the Department may

release information regarding an infected person pursuant to G.S. 130A-143(3)

only when the local health department or the Department has provided direct

medical care to the infected person and refers the person to or consults with

the health care provider to whom the information is released.

(12)         Notwithstanding Rule .0201(d) of this Section, a

local or state health director may require, as a part of an isolation order

issued in accordance with G.S. 130A-145, compliance with a plan to assist the

individual to comply with control measures.  The plan shall be designed to meet

the specific needs of the individual and may include one or more of the

following available and appropriate services:

(a)           substance abuse counseling and treatment;

(b)           mental health counseling and treatment; and

(c)           education and counseling sessions about HIV,

HIV transmission, and behavior change required to prevent transmission.

(13)         The Division of Public Health shall conduct a

partner notification program to assist in the notification and counseling of

partners of HIV infected persons.

(14)         Every pregnant woman shall be offered HIV testing by

her attending physician at her first prenatal visit and in the third

trimester.  The attending physician shall test the pregnant woman for HIV

infection, unless the pregnant woman refuses to provide informed consent

pursuant to G.S. 130A-148(h).  If there is no record at labor and delivery of

an HIV test result during the current pregnancy for the pregnant woman, the

attending physician shall inform the pregnant woman that an HIV test will be

performed, explain the reasons for testing, and the woman shall be tested for

HIV without consent using a rapid HIV test unless it reasonably appears that

the test cannot be performed without endangering the safety of the pregnant

woman or the person administering the test.  If the pregnant woman cannot be

tested, an existing specimen, if one exists that was collected within the last

24 hours, shall be tested using a rapid HIV test.  The attending physician must

provide the woman with the test results as soon as possible.  However, labor

and delivery providers who do not currently have the capacity to perform rapid

HIV testing are not required to use a rapid HIV test until January 1, 2009.

(15)         If an infant is delivered by a woman with no record

of the result of an HIV test conducted during the pregnancy and if the woman

was not tested for HIV during labor and delivery, the fact that the mother has

not been tested creates a reasonable suspicion pursuant to G.S. 130A-148(h)

that the newborn has HIV infection and the infant shall be tested for HIV.  An

infant born in the previous 12 hours shall be tested using a rapid HIV test. 

However, providers who do not currently have the capacity to perform rapid HIV

testing shall not be required to use a rapid HIV test until January 1, 2009.

(16)         Testing for HIV may be offered as part of routine

laboratory testing panels using a general consent which is obtained from the

patient for treatment and routine laboratory testing, so long as the patient is

notified that they are being tested for HIV and given the opportunity to

refuse.

 

History Note:        Authority G.S. 130A‑135; 130A‑144;

130A‑145; 130A‑148(h);

Temporary Rule Eff. February

1, 1988, for a period of 180 days to expire on July

29, 1988;

Eff. March 1, 1988;

Amended Eff. February

1, 1990; November 1, 1989; June 1, 1989;

Temporary Amendment Eff. January

7, 1991 for a period of 180 days to expire on July

6, 1991;

Amended Eff. May

1, 1991;

Recodified from 15A NCAC 19A .0201 (d) and (e) Eff. June

11, 1991;

Amended Eff. August

1, 1995; October 1, 1994; January 4, 1994; October

1, 1992;

Temporary Amendment Eff. February

18, 2002; June 1, 2001;

Amended Eff. November 1, 2007; April 1, 2005; April 1,

2003.

 

10A NCAC 41A .0203       CONTROL MEASURES ‑ HEPATITIS B

(a)  The following are the control measures for hepatitis B

infection.  The infected persons shall:

(1)           refrain from sexual intercourse unless

condoms are used except when the partner is known to be infected with or immune

to hepatitis B;

(2)           not share needles or syringes;

(3)           not donate or sell blood, plasma,

platelets, other blood products, semen, ova, tissues, organs, or breast milk;

(4)           if the time of initial infection is known,

identify to the local health director all sexual intercourse and needle

partners since the date of infection; and, if the date of initial infection is

unknown, identify persons who have been sexual intercourse or needle partners

during the previous six months;

(5)           for the duration of the infection, notify

future sexual intercourse partners of the infection and refer them to their

attending physician or the local health director for control measures; and for

the duration of the infection, notify the local health director of all new

sexual intercourse partners;

(6)           identify to the local health director all

current household contacts;

(7)           be tested six months after diagnosis to

determine if they are chronic carriers, and when necessary to determine

appropriate control measures for persons exposed pursuant to Paragraph (b) of

this Rule;

(8)           comply with all control measures for

hepatitis B infection specified in Paragraph (a) of 10A NCAC 41A .0201, in

those instances where such control measures do not conflict with other

requirements of this Rule.

(b)  The following are the control measures for persons

reasonably suspected of being exposed:

(1)           when a person has had a sexual intercourse

exposure to hepatitis B infection, the person shall be tested;

(2)           after testing, when a susceptible person

has had sexual intercourse exposure to hepatitis B infection, the person shall

be given a dose appropriate for body weight of hepatitis B immune globulin and

hepatitis B vaccination as soon as possible; hepatitis B immune globulin shall

be given no later than two weeks after the last exposure;

(3)           when a person is a household contact,

sexual intercourse or needle sharing contact of a person who has remained

infected with hepatitis B for six months or longer, the partner or household

contact, if susceptible and at risk of continued exposure, shall be vaccinated

against hepatitis B;

(4)           when a health care worker or other person

has a needlestick, non‑intact skin, or mucous membrane exposure to blood

or body fluids that, if the source were infected with the hepatitis B virus,

would pose a significant risk of hepatitis B transmission, the following shall

apply:

(A)          when the source is known, the source person shall be

tested for hepatitis B infection, unless already known to be infected;

(B)          when the source is infected with hepatitis B and the

exposed person is:

(i)            vaccinated, the exposed person shall be tested

for anti‑HBs and, if anti-HBs is unknown or less than 10

milli-International Units per ml, receive hepatitis B vaccination and hepatitis

B immune globulin as soon as possible; hepatitis B immune globulin shall be

given no later than seven days after exposure; 

(ii)           not vaccinated, the exposed person shall be

given a dose appropriate for body weight of hepatitis B immune globulin

immediately and begin vaccination with hepatitis B vaccine within seven days;

(C)          when the source is unknown, the determination of

whether hepatitis B immunization is required shall be made in accordance with

current published Control of Communicable Diseases Manual and Centers for

Disease Control and Prevention guidelines.  Copies of the Control of

Communicable Diseases Manual may be purchased from the American Public Health

Association, Publication Sales Department, Post Office Box 753, Waldora, MD

20604 for a cost of twenty-two dollars ($22.00) each plus five dollars ($5.00)

shipping and handling.  Copies of Center for Disease Control and Prevention

guidelines contained in the Morbidity and Mortality Weekly Report may be

purchased from the Superintendent of Documents, U.S. Government Printing

Office, Washington, DC 20402 for a cost of three dollars fifty cents ($3.50)

each.  Copies of both publications are available for inspection in the General

Communicable Disease Control Branch, Cooper Memorial Health Building,

225 N. McDowell Street, Raleigh, North Carolina 27603-1382.

(5)           infants born to HBsAg-positive mothers

shall be given hepatitis B vaccination and hepatitis B immune globulin within

12 hours of birth or as soon as possible after the infant is stabilized. 

Additional doses of hepatitis B vaccine shall be given in accordance with current

published Control of Communicable Diseases Manual and Centers for Disease

Control and Prevention Guidelines.  The infant shall be tested for the presence

of HBsAg and anti-HBs within three to nine months after the last dose of the

regular series of vaccine; if required because of failure to develop immunity

after the regular series, additional doses shall be given in accordance with

current published Control of Communicable Diseases Manual and Centers for

Disease Control and Prevention guidelines.  Copies of the Control of

Communicable Diseases Manual may be purchased from the American Public Health

Association, Publication Sales Department, Post Office Box 753, Waldora, MD

20604 for a cost of twenty-two dollars ($22.00) each plus five dollars ($5.00)

shipping and handling.  Copies of Center for Disease Control and Prevention

guidelines contained in the Morbidity and Mortality Weekly Report may be

purchased from the Superintendent of Documents, U.S. Government Printing

Office, Washington, DC 20402 for a cost of three dollars fifty cents ($3.50)

each.  Copies of both publications are available for inspection in the General

Communicable Disease Control Branch, Cooper Memorial Health Building,

225 N. McDowell Street, Raleigh, North Carolina 27603-1382;

(6)           infants born to mothers whose HBsAg status

is unknown shall be given  hepatitis B vaccine within 12 hours of birth and the

mother tested.  If the tested mother is found to be HBsAg-positive, the infant

shall be given hepatitis B immune globulin as soon as possible and no later

than seven days after birth;

(7)           when an acutely infected person is a

primary caregiver of a susceptible infant less than 12 months of age, the

infant shall receive an appropriate dose of hepatitis B immune globulin and

hepatitis vaccinations in accordance with current published Control of

Communicable Diseases Manual and Centers for Disease Control and Prevention

Guidelines.  Copies of the Control of Communicable Diseases Manual may be

purchased from the American Public Health Association, Publication Sales

Department, Post Office Box 753, Waldora, MD 20604 for a cost of twenty-two

dollars ($22.00) each plus five dollars ($5.00) shipping and handling.  Copies

of Center for Disease Control and Prevention guidelines contained in the Morbidity

and Mortality Weekly Report may be purchased from the Superintendent of

Documents, U.S. Government Printing Office, Washington, DC 20402

for a cost of three dollars fifty cents ($3.50) each.  Copies of both

publications are available for inspection in the General Communicable Disease

Control Branch, Cooper Memorial Health Building, 225 N. McDowell Street, Raleigh,

North Carolina 27603-1382.

(c)  The attending physician shall advise all patients known

to be at high risk, including injection drug users, men who have sex with men,

hemodialysis patients, and patients who receive multiple transfusions of blood

products, that they should be vaccinated against hepatitis B if susceptible. 

The attending physician shall also recommend that hepatitis B chronic carriers

receive hepatitis A vaccine (if susceptible).

(d)  The following persons shall be tested for and reported

in accordance with 10A NCAC 41A .0101 if positive for hepatitis B infection:

(1)           pregnant women unless known to be infected;

and

(2)           donors of blood, plasma, platelets, other

blood products, semen, ova, tissues, or organs.

(e)  The attending physician of a child who is infected with

hepatitis B virus and who may pose a significant risk of transmission in the

school or day care setting because of open, oozing wounds or because of

behavioral abnormalities such as biting shall notify the local health

director.  The local health director shall consult with the attending physician

and investigate the circumstances.

(f)  If the child referred to in Paragraph (e) of this Rule

is in school or scheduled for admission and the local health director

determines that there may be a significant risk of transmission, the local

health director shall consult with an interdisciplinary committee, which shall

include school personnel, a medical expert, and the child's parent or guardian

to assist in the investigation and determination of risk.  The local health

director shall notify the superintendent or private school director of the need

to appoint such an interdisciplinary committee. If the superintendent or

private school director establishes such a committee within three days of

notification, the local health director shall consult with this committee.  If

the superintendent or private school director does not establish such a

committee within three days of notification, the local health director shall

establish such a committee.

(g)  If the child referred to in Paragraph (e) of this Rule

is in school or scheduled for admission and the local health director determines,

after consultation with the committee, that a significant risk of transmission

exists, the local health director shall:

(1)           notify the parents;

(2)           notify the committee;

(3)           assist the committee in determining whether

an adjustment can be made to the student's school program to eliminate

significant risks of transmission;

(4)           determine if an alternative educational

setting is necessary to protect the public health;

(5)           instruct the superintendent or private

school director concerning protective measures to be implemented in the

alternative educational setting developed by school personnel; and

(6)           consult with the superintendent or private

school director to determine which school personnel directly involved with the

child need to be notified of the hepatitis B virus infection in order to

prevent transmission and ensure that these persons are instructed regarding the

necessity for protecting confidentiality.

(h)  If the child referred to in Paragraph (e) of this Rule

is in day care and the local health director determines that there is a

significant risk of transmission, the local health director shall notify the

parents that the child must be placed in an alternate child care setting that

eliminates the significant risk of transmission.

 

History Note:        Authority G.S. 130A‑135; 130A‑144

Eff. February 1, 1990;

Amended Eff. October

1, 1990;

Recodified from 15A NCAC 19A .0201(i) Eff. June

11, 1991;

Amended Eff. August

1, 1998; October 1, 1994;

Temporary Amendment Eff. February

18, 2002;

Amended Eff. April

1, 2003.

 

10A NCAC 41A .0204       CONTROL MEASURES - SEXUALLY TRANSMITTED

DISEASES

(a)  Local health departments shall provide diagnosis,

testing, treatment, follow-up, and preventive services for syphilis, gonorrhea,

chlamydia, nongonococcal urethritis, mucopurulent cervicitis, chancroid,

lymphogranuloma venereum, and granuloma inguinale.  These services shall be

provided upon request and at no charge to the patient.

(b)  Persons infected with, exposed to, or reasonably

suspected of being infected with gonorrhea, chlamydia, non-gonococcal

urethritis, and mucopurulent cervicitis shall:

(1)           Refrain from sexual intercourse until

examined and diagnosed and treatment is completed, and all lesions are healed;

(2)           Be tested, treated, and re-evaluated in

accordance with the STD Treatment Guidelines published by the U.S. Public

Health Service.  The recommendations contained in the STD Treatment Guidelines are

the required control measures for testing, treatment, and follow-up for

gonorrhea, chlamydia, nongonococcal urethritis, and mucopurulent cervicitis,

and are incorporated by reference including subsequent amendments and

editions.  A copy  of this publication is on file for public viewing with the

and a copy may be obtained free of charge by writing the Division of Public

Health, 1915 Mail Service Center, Raleigh, North Carolina 27699-1915, and

requesting a copy.  However, urethral Gram stains may be used for diagnosis of

males rather than gonorrhea cultures unless treatment has failed;

(3)           Notify all sexual partners from 30 days

before the onset of symptoms to completion of therapy that they must be

evaluated by a physician or local health department.

(c)  Persons infected with, exposed to, or reasonably

suspected of being infected with syphilis, lymphogranuloma venereum, granuloma

inguinale, and chancroid shall:

(1)           Refrain from sexual intercourse until

examined and diagnosed and treatment is completed, and all lesions are healed;

(2)           Be tested, treated, and re-evaluated in

accordance with the STD Treatment Guidelines published by t h e U.S. Public

Health Service.  The recommendations contained in the STD Treatment Guidelines are

the required control measures for testing, treatment, and follow-up for

syphilis, lymphogranuloma venereum, granuloma inguinale, and chancroid, except

that chancroid cultures are not required;

(3)           Give names to a disease intervention

specialist employed by the local health department or by the Division of Public

Health for contact tracing of all sexual partners and others as listed in this

Rule:

(A)          for syphilis:

(i)            congenital - parents and siblings;

(ii)           primary - all partners from three months before

the onset of symptoms to completion of therapy and healing of lesions;

(iii)          secondary - all partners from six months before

the onset of symptoms to completion of therapy and healing of lesions; and

(iv)          latent - all partners from 12 months before the

onset of symptoms to completion of therapy and healing of lesions and, in

addition, for women with late latent, spouses and children;

(B)          for lymphogranuloma venereum:

(i)            if there is a primary lesion and no buboes, all

partners from 30 days before the onset of symptoms to completion of therapy and

healing of lesions; and

(ii)           if there are buboes all partners from six

months before the onset of symptoms to completion of therapy and healing of

lesions;

(C)          for granuloma inguinale - all partners from three

months before the onset of symptoms to completion of therapy and healing of

lesions; and

(D)          or chancroid - all partners from ten days before the

onset of symptoms to completion of therapy and healing of lesions.

(d)  All persons evaluated or reasonably suspected of being

infected with any sexually transmitted disease shall be tested for syphilis,

encouraged to be tested confidentially for HIV, and counseled about how to

reduce the risk of acquiring sexually transmitted disease, including the use of

condoms.

(e)  All pregnant women shall be tested for syphilis,

chlamydia and gonorrhea at the first prenatal visit.  All pregnant women shall

be tested for syphilis between 28 and 30 weeks of gestation and at delivery.  Hospitals

shall determine the syphilis serologic status of the mother prior to discharge

of the newborn  so that if necessary the newborn can be evaluated and treated

as provided in (c)(2) of this rule.  Pregnant women 25 years of age and younger

shall be tested for chlamydia and gonorrhea in the third trimester or at delivery

if the woman was not tested in the third trimester.

(f)  Any woman who delivers a stillborn infant shall be

tested for syphilis.

(g) All newborn infants shall be treated prophylactically

against gonococcal ophthalmia neonatorum in accordance with the STD Treatment

Guidelines published by the U.S. Public Health Service.  The recommendations

contained in the STD Treatment Guidelines are the required prophylactic

treatment against gonococcal ophthalmia neonatorum.

 

History Note:        Authority G. S. 130A-135; 130A-144;

Eff. December 1, 1991;

Amended Eff. April 1, 2008; November 1, 2007; April 1,

2003; July 1, 1993.

 

10A NCAC 41A .0205       CONTROL MEASURES – TUBERCULOSIS

(a)  The local health director shall investigate all cases

of tuberculosis disease and their contacts in accordance with recommendations

and guidelines published by the Centers for Disease Control and Prevention

which are hereby incorporated by reference including subsequent amendments and

editions.  The recommendations and guidelines are the required control measures

for tuberculosis, except as otherwise provided in this Rule.  A copy of the

recommendations and guidelines is available by contacting the Division of

Public Health, 1931 Mail Service Center, Raleigh, North Carolina 27699-1931 or

by accessing the Centers for Disease Control and Prevention website at http://www.cdc.gov/tb.

(b)  The following persons shall have a tuberculin skin test

(TST) or Interferon Gamma Release Assay (IGRA) administered in accordance with

recommendations and guidelines published by the Centers for Disease Control and

Prevention:

(1)           Household and other high priority contacts

of active cases of pulmonary and laryngeal tuberculosis. For purposes of this

Rule, a high priority contact is defined in accordance with Centers for Disease

Control and Prevention guidelines.  If the contact's initial skin or IGRA test

is negative, and the case is confirmed by culture, a repeat skin or IGRA test

shall be performed 8 to 10 weeks after the exposure has ended;

(2)           Persons reasonably suspected of having

tuberculosis disease;

(3)           Inmates in the custody of the Department of

Public Safety, Division of Adult Correction upon incarceration, and annually

thereafter;

(4)           Persons with HIV infection or AIDS.

(c)  The following persons shall be tested using a two-step

skin test method or a single IGRA test, administered in accordance with

recommendations and guidelines published by the Centers for Disease Control and

Prevention:

(1)           Staff with direct inmate contact in the

Department of Public Safety, Division of Adult Correction upon employment;

(2)           Staff of licensed nursing homes or adult

care homes upon employment;

(3)           Residents upon admission to licensed nursing

homes or adult care homes.  If the individual is being admitted directly from

another hospital, licensed nursing home or adult care home in North Carolina

and there is documentation of a two-step skin test or a single IGRA test, the

individual does not need to be retested;

(4)           Staff in adult day care centers providing

care for persons with HIV infection or AIDS upon employment.

(d)  Except as provided in the last sentence of Subparagraph

(c)(3) of this Rule, persons listed in Paragraph (c) of this rule shall be

required only to have a single TST or IGRA in the following situations:

(1)           If the person has ever had a two-step skin

test; or

(2)           If the person has had a single skin test

within the last twelve months.

(e)  Persons with a positive tuberculin skin test or IGRA

shall be evaluated by an interview to screen for symptoms and a chest x-ray if

they do not have a documented chest x-ray that was performed on the date of the

positive test or later.

(f)  Treatment and follow-up for tuberculosis infection or

disease shall be in accordance with the recommendations and guidelines from the

Centers for Disease Control and Prevention.

(g)  Persons with active tuberculosis disease shall complete

a standard multi-drug regimen, and shall be managed using Directly Observed

Therapy (DOT), which is the actual observation of medication ingestion by a

health care worker (HCW).

If a standard multi-drug regimen cannot be used, the

attending physician shall consult with the state Tuberculosis Medical Director

or designee on the treatment plan.

(h)  Persons with suspected or known active pulmonary or

laryngeal tuberculosis who have sputum smears  positive for acid fast bacilli shall

be considered infectious and shall be managed using airborne precautions including

respiratory isolation or isolation in their home with no new persons exposed. 

These individuals are considered noninfectious and use of airborne precautions,

precautions including respiratory isolation or isolation in their home may be

discontinued when:

(1)           Sputum specimen results meet Centers for

Disease Control and Prevention criteria for discontinuation of respiratory

isolation;

(2)           They have two consecutive sputum smears

collected at least eight hours apart which are negative;

(3)           It has been at least seven days since the

last positive sputum smear; and

(4)           They have been compliant on tuberculosis

medications to which the organism is susceptible and there is evidence of

clinical response to tuberculosis treatment.

(i)  Persons with suspected or known active pulmonary or

laryngeal tuberculosis who are initially sputum smear negative require

respiratory isolation until they have been started on tuberculosis treatment to

which the organism is susceptible and there is evidence of clinical response to

treatment.

 

History Note:        Authority G.S. 130A-135; 130A-144;

Eff. March 1, 1992;

Amended Eff. April 1, 2006; April 1, 2003; August 1,

1998; October 1, 1994;

Temporary Amendment Eff. August 1, 2011;

Amended Eff. July 1, 2012.

 

10A NCAC 41A .0206       INFECTION PREVENTION – HEALTH CARE

SETTINGS

(a)  The following definitions apply throughout this Rule:

(1)           "Health care organization" means

a hospital; clinic; physician, dentist, podiatrist, optometrist, or

chiropractic office; home care agency; nursing home; local health department;

community health center; mental health facility; hospice; ambulatory surgical

facility; urgent care center; emergency room; Emergency Medical Service (EMS)

agency; pharmacies where a health practitioner offers clinical services; or any

other organization that provides clinical care.

(2)           "Invasive procedure" means entry

into tissues, cavities, or organs or repair of traumatic injuries.  The term

includes the use of needles to puncture skin, vaginal and cesarean deliveries,

surgery, and dental procedures during which bleeding occurs or the potential

for bleeding exists.

(3)           "Non-contiguous" means not

physically connected.

(b)  In order to prevent transmission of HIV, hepatitis B,

hepatitis C and other bloodborne pathogens each health care organization that

performs invasive procedures shall implement a written infection control policy. 

The health care organization shall ensure that health care workers in its

employ or who have staff privileges are trained in the principles of infection

control and the practices required by the policy; require and monitor

compliance with the policy; and update the policy as needed to prevent

transmission of HIV, hepatitis B, hepatitis C and other bloodborne pathogens. 

The health care organization shall designate one on-site staff member for each

noncontiguous facility to direct these activities.  The designated staff member

in each health care facility shall complete a course in infection control

approved by the Department.  The Department shall approve a course that

addresses:

(1)           Epidemiologic principles of infectious

disease;

(2)           Principles and practice of asepsis;

(3)           Sterilization, disinfection, and

sanitation;

(4)           Universal blood and body fluid precautions;

(5)           Safe injection practices;

(6)           Engineering controls to reduce the risk of

sharp injuries;

(7)           Disposal of sharps; and

(8)           Techniques that reduce the risk of sharp

injuries to health care workers.

(c)  The infection control policy required by this Rule

shall address the following components that are necessary to prevent

transmission of HIV, hepatitis B, hepatitis C and other bloodborne pathogens:

(1)           Sterilization and disinfection, including a

schedule for maintenance and microbiologic monitoring of equipment; the policy

shall require documentation of maintenance and monitoring;

(2)           Sanitation of rooms and equipment,

including cleaning procedures, agents, and schedules;

(3)           Accessibility of infection control devices

and supplies; and

(4)           Procedures to be followed in implementing

10A NCAC 41A .0202(4) and .0203(b)(4) when a health care provider or a patient

has an exposure to blood or other body fluids of another person in a manner

that poses a significant risk of transmission of HIV or hepatitis B.

(d)  Health care workers and emergency responders shall,

with all patients, follow Centers for Disease Control and Prevention Guidelines

on blood and body fluid precautions incorporated by reference in 10A NCAC 41A

.0201.

(e)  Health care workers who have exudative lesions or weeping

dermatitis shall refrain from handling patient care equipment and devices used

in performing invasive procedures and from all direct patient care that

involves the potential for contact of the patient, equipment, or devices with

the lesion or dermatitis until the condition resolves.

(f)  All equipment used to puncture skin, mucous membranes,

or other tissues in medical, dental, or other settings must be disposed of in

accordance with 15A NCAC 13B .1200 after use or sterilized prior to reuse.

 

History Note:        Authority G.S. 130A‑144; 130A‑145;

130A-147;

Eff. October 1, 1992;

Amended Eff. January 1, 2010; December 1, 2003; July 1,

1994; January 4, 1994.

 

10A NCAC 41A .0207       HIV AND HEPATITIS B INFECTED HEALTH CARE

WORKERS

(a)  The following definitions shall apply throughout this

Rule:

(1)           "Surgical or obstetrical

procedures" means vaginal deliveries or surgical entry into tissues,

cavities, or organs.  The term does not include phlebotomy; administration of

intramuscular, intradermal, or subcutaneous injections; needle biopsies; needle

aspirations; lumbar punctures; angiographic procedures; endoscopic and

bronchoscopic procedures; or placing or maintaining peripheral or central

intravascular lines.

(2)           "Dental procedure" means any

dental procedure involving manipulation, cutting, or removal of oral or

perioral tissues, including tooth structure during which bleeding occurs or the

potential for bleeding exists.  The term does not include the brushing of

teeth.

(b)  All health care workers who perform surgical or

obstetrical procedures or dental procedures and who know themselves to be

infected with HIV or hepatitis B shall notify the State Health Director.  Health

care workers who assist in these procedures in a manner that may result in

exposure of patients to their blood and who know themselves to be infected with

HIV or hepatitis B shall also notify the State Health Director.  The

notification shall be made in writing to the Chief, Communicable Disease

Control Branch, 1902 Mail Service Center, Raleigh, NC 27699-1902..

(c)  The State Health Director shall investigate the

practice of any infected health care worker and the risk of transmission to

patients.  The investigation may include review of medical and work records and

consultation with health care professionals who may have information necessary

to evaluate the clinical condition or practice of the infected health care

worker.  The attending physician of the infected health care worker shall be

consulted.  The State Health Director shall protect the confidentiality of the

infected health care worker and may disclose the worker's infection status only

when essential to the conduct of the investigation or periodic reviews pursuant

to Paragraph (h) of this Rule.  When the health care worker's infection status

is disclosed, the State Health Director shall give instructions regarding the

requirement for protecting confidentiality.

(d)  If the State Health Director determines that there may

be a significant risk of transmission of HIV or hepatitis B to patients, the

State Health Director shall appoint an expert panel to evaluate the risk of

transmission to patients, and review the practice, skills, and clinical

condition of the infected health care worker, as well as the nature of the

surgical or obstetrical procedures or dental procedures performed and operative

and infection control techniques used.  Each expert panel shall include an

infectious disease specialist, an infection control expert, a person who

practices the same occupational specialty as the infected health care worker

and, if the health care worker is a licensed professional, a representative of

the appropriate licensure board.  The panel may include other experts.  The

State Health Director shall consider for appointment recommendations from

health care organizations and local societies of health care professionals.

(e)  The expert panel shall review information collected by

the State Health Director and may request that the State Health Director obtain

additional information as needed.  The State Health Director shall not reveal

to the panel the identity of the infected health care worker.  The infected

health care worker and the health care worker's attending physician shall be

given an opportunity to present information to the panel.  The panel shall make

recommendations to the State Health Director that address the following:

(1)           Restrictions that are necessary to prevent

transmission from the infected health care worker to patients;

(2)           Identification of patients that have been

exposed to a significant risk of transmission of HIV or hepatitis B; and

(3)           Periodic review of the clinical condition

and practice of the infected health care worker.

(f)  If, prior to receipt of the recommendations of the

expert panel, the State Health Director determines that immediate practice

restrictions are necessary to prevent an imminent threat to the public health,

the State Health Director shall issue an isolation order pursuant to G.S. 130A‑145. 

The isolation order shall require cessation or modification of some or all

surgical or obstetrical procedures or dental procedures to the extent necessary

to prevent an imminent threat to the public health.  This isolation order shall

remain in effect until an isolation order is issued pursuant to Paragraph (g)

of this Rule or until the State Health Director determines the imminent threat

to the public health no longer exists.

(g)  After consideration of the recommendations of the

expert panel, the State Health Director shall issue an isolation order pursuant

to G.S. 130A‑145.  The isolation order shall require any health care

worker who is allowed to continue performing surgical or obstetrical procedures

or dental procedures to, within a time period specified by the State Health

Director, successfully complete a course in infection control procedures

approved by the Department of Health and Human Services, General Communicable

Disease Control Branch, in accordance with 10A NCAC 41A .0206(e).  The

isolation order shall require practice restrictions, such as cessation or

modification of some or all surgical or obstetrical procedures or dental

procedures, to the extent necessary to prevent a significant risk of

transmission of HIV or hepatitis B to patients.  The isolation order shall

prohibit the performance of procedures that cannot be modified to avoid a

significant risk of transmission.  If the State Health Director determines that

there has been a significant risk of transmission of HIV or hepatitis B to a

patient, the State Health Director shall notify the patient or assist the

health care worker to notify the patient.

(h)  The State Health Director shall request the assistance

of one or more health care professionals to obtain information needed to

periodically review the clinical condition and practice of the infected health

care worker who performs or assists in surgical or obstetrical procedures or

dental procedures.

(i)  An infected health care worker who has been evaluated

by the State Health Director shall notify the State Health Director prior to a

change in practice involving surgical or obstetrical procedures or dental

procedures. The infected health care worker shall not make the proposed change

without approval from the State Health Director.  If the State Health Director

makes a determination in accordance with Paragraph (c) of this Rule that there

is a significant risk of transmission of HIV or hepatitis B to patients, the

State Health Director shall appoint an expert panel in accordance with

Paragraph (d) of this Rule.  Otherwise, the State Health Director shall notify

the health care worker that he or she may make the proposed change in practice.

(j)  If practice restrictions are imposed on a licensed

health care worker, a copy of the isolation order shall be provided to the

appropriate licensure board.  The State Health Director shall report violations

of the isolation order to the appropriate licensure board.  The licensure board

shall report to the State Health Director any information about the infected

health care worker that may be relevant to the risk of transmission of HIV or

hepatitis B to patients.

 

History Note:        Authority G.S. 130A‑144; 130A‑145;

Eff. October 1, 1992;

Amended Eff. April

1, 2003.

 

10A NCAC 41A .0208       CONTROL MEASURES -- SMALLPOX; VACCINIA

DISEASE

(a)  Guidelines and recommended actions for prevention of

the spread of smallpox and for prevention of the spread of vaccinia published

by the Center for Disease Control and Prevention (CDC) shall supercede those

contained in the control of Communicable Disease Manual and are incorporated by

reference, including subsequent amendments and editions.  Copies of CDC

guidelines contained in the Morbidity and Mortality weekly reports may be

purchased from the Superintendent of Documents, US Government Printing Office, Washington

DC 20402 for a total cost of three dollars and fifty cents ($3.50) each.

(b)  The attending physician of a person vaccinated against

smallpox shall report to the local health department the existence of any of

the following:

(1)           autoinnoculation;

(2)           generalized vaccinia;

(3)           eczema vaccinatum;

(4)           progressive vaccinia; and

(5)           post vaccination encephalitis.

The attending physician shall make the report to the local

health department within 24 hours.  The local health department shall notify

the Division of Public Health within 24 hours.

(c)  The physician responsible for vaccinating a person

against smallpox and the physician diagnosing a person with vaccinia disease

shall instruct the patient to follow CDC guidelines for the prevention of the

spread of vaccinia adopted by reference in Paragraph (a) of this Rule.  The

patient shall follow these guidelines.

(d)  The State Health Director or a local health director

may use isolation authority pursuant to G.S. 130A-145 when necessary to prevent

the spread of smallpox or vaccinia virus.

 

History Note:        Authority G.S.  130A‑144;

Temporary Adoption Eff. February 13, 2003;

Eff. August 1, 2004.

 

10A NCAC 41A .0209       LABORATORY TESTING

All laboratories shall do the following:

(1)           When Neisseria meningitidis is isolated from a

normally sterile site, test the organism for specific serogroup or send the

isolate to the State Laboratory of Public Health for serogrouping;

(2)           When a stool culture is requested on a specimen

from a person with bloody diarrhea, culture the stool for shiga-toxin producing

Escherichia coli or send the specimen to the State Laboratory of Public Health;



(3)           When Haemophilus influenzae is isolated, test the

organism for specific serogroup or send the isolate to the State Laboratory of

Public Health for serogrouping; and

(4)           When Mycobacterium tuberculosis complex is

isolated, test the organism for specific restriction fragment length

polymorphism (RFLP) or send the isolate, or a subculture of the isolate, to the

State Laboratory of Public Health for genotyping.

 

History Note:        Authority G.S. 130A‑139;

Eff. October 1, 1994;

Temporary Amendment Eff. February

18, 2002;

Amended Eff. April

1, 2004; April 1, 2003.

 

10A NCAC 41A .0210       DUTIES OF ATTENDING PHYSICIANS

Immediately upon making a diagnosis of or reasonably

suspecting a communicable disease or communicable condition for which control

measures are provided in Rule .0201, .0202 or .0203 of this Section, the attending

physician shall instruct the patient and any other person specified in those

control measures to carry out those control measures and shall give

sufficiently detailed instructions for proper compliance, or the physician

shall request the local health director to give such instruction.  When making

the initial telephone report for diseases and conditions required to be

reported within 24 hours, the physician shall inform the local health director

of the control measures given.

 

History Note:        Filed as a Temporary Rule Eff. February 1, 1988, for a period of 180 days to expire on July

29, 1988;

Authority G.S. 130A‑144;

Eff. March 1, 1988;

Recodified from 15A NCAC 19A .0202 Eff. June

11, 1991.

 

10A NCAC 41A .0211       DUTIES OF OTHER PERSONS

(a)  The local health director may reveal the identity and

diagnosis of a person with a reportable communicable disease or communicable

condition or other communicable disease or communicable condition which represents

a significant threat to the public health to those persons specified in

Paragraph (b) when disclosure is necessary to prevent transmission in the

facility or establishment for which they are responsible.  The local health

director shall ensure that all persons so notified are instructed regarding the

necessity for protecting confidentiality.

(b)  The following persons shall require that any person

about whom they are notified pursuant to Paragraph (a) comply with control

measures given by the local health director to prevent transmission in the

facility or establishment:

(1)           the principal of any private or public

school;

(2)           employers;

(3)           superintendents or directors of all public

or private institutions, hospitals, or jails; and

(4)           operators of a child day care center, child

day care home, or other child care providers.

(c)  The provisions of Paragraphs (a) and (b) shall not

apply with regard to gonorrhea, syphilis, chancroid, granuloma inguinale,

lymphogranuloma venereum, chlamydia, non‑gonococcal urethritis, AIDS, and

HIV infection. However, persons may be notified with regard to these diseases

and conditions in accordance with 10A NCAC 41A .0201, .0202 or .0203 of this

Section.

 

History Note:        Filed as a Temporary Rule Eff. February 1, 1988, for a period of 180 days to expire on July

29, 1988;

Authority G.S. 130A‑143; 130A‑144;

Eff. March 1, 1988;

Amended Eff. June

1, 1989;

Recodified from 15A NCAC 19A .0203 Eff. June

11, 1991.

 

10A NCAC 41A .0212       HANDLING AND TRANSPORTATION OF BODIES

(a) It shall be the duty of the physician attending any

person who dies and is known to be infected with HIV, plague, or hepatitis B or

any person who dies and is known or reasonably suspected to be infected with

smallpox, rabies, severe acute respiratory syndrome (SARS), or

Jakob-Creutzfeldt to provide written notification to all individuals handling

the body of the proper precautions to prevent infection. This written

notification shall be provided to funeral service personnel at the time the

body is removed from any hospital, nursing home, or other health care facility.

When the patient dies in a location other than a health care facility, the

attending physician shall notify the funeral service personnel verbally of the

precautions required as soon as the physician becomes aware of the death. These

precautions are noted in Paragraphs (b) and (c).

(b) The body of any person who died and is known or

reasonably suspected to be infected with smallpox or severe acute respiratory

syndrome (SARS) or any person who died and is known to be infected with plague

shall not be embalmed. The body shall be enclosed in a strong, tightly sealed

outer case which will prevent leakage or escape of odors as soon as possible

after death and before the body is removed from the hospital room, home,

building, or other premises where the death occurred. This case shall not be

reopened except with the consent of the local health director.  Nothing in this

Paragraph shall prohibit cremation. 

(c) Persons handling the body of any person who died and is

known to be infected with HIV or hepatitis B or any person who died and is

known or reasonably suspected to be infected with Jakob-Creutzfeldt or rabies

shall be provided written notification to observe blood and body fluid

precautions.

 

History Note:        Authority G.S. 130A-144; 130A-146;

Temporary Rule Eff. February 1, 1988, for a period of 180

days to expire on July 29, 1988; Eff. March 1, 1988; Recodified from 15A NCAC

19A .0204 Eff. June 11, 1991;

Temporary Amendment Eff. November 1, 2003;

Amended Eff. April 1, 2004.

 

10A NCAC 41A .0213       CONTROL MEASURES -- SARS

Guidelines and recommended actions for prevention of the

spread of Severe Acute Respiratory Syndrome (SARS) published by the Centers for

Disease Control and Prevention (CDC) shall be the required control measures for

SARS and are incorporated by reference, including subsequent amendments and

editions.  Copies of CDC guidelines contained in the Morbidity and Mortality

weekly reports may be purchased from the Superintendent of Documents, US

Government Printing Office, Washington DC 20402 for a total cost of three

dollars and fifty cents ($3.50) each.

 

History Note:        Authority G.S. 130A‑144;

Temporary Adoption Eff. May 16, 2003;

Eff. August 1, 2004.

 

10A NCAC 41A .0214       CONTROL MEASURES - HEPATITIS C

The following are the control measures for hepatitis C

infection:

(1)           Infected persons shall not:

(a)           share needles or syringes, any other

drug-related equipment or paraphernalia, or personal items, such as razors,

that may be contaminated with blood through previous use; or

(b)           donate or sell blood, plasma, platelets, or

other blood products.

(2)           Persons with acute hepatitis C infection shall:

(a)           if the date of initial infection is known,

identify to the local health director all needle partners since the date of

infection;

(b)           if the date of initial infection is unknown,

identify persons who have been needle partners during the previous six months.

(3)           The attending physician shall:

(a)           advise all patients known to be at high

risk, including injection drug users, hemodialysis patients, patients who

received blood transfusions or solid organ transplants before July 1992,

patients who received clotting factor concentrates made before 1987, persons

with HIV infection, and persons with known exposure to hepatitis C, that they

should be tested for hepatitis C;

(b)           advise infected persons of the potential for

transmission to others via blood or body fluids;

(c)           provide or recommend that the infected

patient seek medical evaluation for the presence or development of chronic

liver disease; and

(d)           recommend that persons with chronic

hepatitis C receive hepatitis A and hepatitis B vaccines unless serological

testing indicates that they are immune to these infections by virtue of past

infection or vaccination.

(4)           When a health care worker or other person has a

needlestick, non-intact skin, or mucous membrane exposure to blood or body

fluids that would pose a significant risk of hepatitis C transmission if the

source were infected with the hepatitis C virus, the following apply:

(a)           When the source is known, the attending

physician or occupational health care provider responsible for the exposed

person, if other than the attending physician of the person whose blood or body

fluids is the source of the exposure, shall notify the attending physician of

the source that an exposure has occurred.  The attending physician of the

source person shall discuss the exposure with the source and, unless the source

is already known to be infected, shall test the source for hepatitis C virus

infection with or without consent unless it reasonably appears that the test

cannot be performed without endangering the safety of the source person or the

person administering the test.  If the source person cannot be tested, an

existing specimen of his or her blood, if one exists, shall be tested. The

attending physician of the source person shall notify the attending physician

of the exposed person of the infection status of the source.

(b)           The attending physician of the exposed

person shall inform the exposed person about the infection status of the source

and shall instruct the exposed person regarding the necessity for protecting

confidentiality. If the source person is infected with hepatitis C virus or the

source person’s infection status is unknown, the attending physician of the

exposed person shall advise the exposed person to seek testing for hepatitis C

virus infection as soon as possible and again four to six months after the

exposure.  If the source person was hepatitis C virus infected, the attending

physician shall inform the exposed person of the measures required in Sub-Items

(1)(a) through (b) of this Rule.

(5)           The Centers for Disease Control and Prevention

(CDC) Nationally Notifiable Diseases and Conditions (NNDC) Current Case

Definitions for Hepatitis C are hereby incorporated by reference, including

subsequent amendments and editions.  The CDC NNDC may be accessed from the

internet at (http://www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm). 

This document is also available for inspection at the North Carolina Division

of Public Health, 1902 Mail Service Center, Raleigh NC 27603.

 

History Note:        Authority G.S. 130A-135; 130A-144;

Eff. April, 1, 2012.

 

SECTION .0300 ‑ SPECIAL CONTROL MEASURES

 

10A NCAC 41A .0301       DEFINITIONS

The following definitions shall apply in the interpretation

of 10A NCAC 41A .0302:

(1)           "Turtle" means any reptile of the order

Testudines.

(2)           "Institution" means a school, college, university,

research laboratory, or other facility having a bona fide research or teaching

interest in turtles.

 

History Note:        Authority G.S. 130A‑144;

Eff. February 1, 1976;

Readopted Eff. December

5, 1977;

Amended Eff. May

1, 1992.

 

10A NCAC 41A .0302       SALE OF TURTLES RESTRICTED

(a)  Purpose of this Regulation.  This Regulation is adopted

to prevent the spread of salmonellosis from pet turtles to humans.

(b)  Sale of Turtles Prohibited.  No turtle shall be sold,

offered for sale, or bartered by any retail or wholesale establishment in North Carolina.

(c)  Sale of Turtles for Scientific, Educational, or Food

Purposes Exempted.  Subsection (b) of this Regulation does not apply to the

sale of turtles to institutions for scientific or educational purposes nor to

the sale of turtles for food purposes.

(d)  Sale of Turtles Outside North Carolina Exempted. 

Notwithstanding the provisions of Subsection (b) of this Regulation, wholesale

establishments in North Carolina dealing in the sale of turtles shall not be

prohibited from selling turtles to other wholesale or retail establishments

outside the State of North Carolina.

(e)  Determination of Compliance.  Authorized agents of the

Department of Environment, Health, and Natural Resources and local health

departments shall have authority to enter any retail or wholesale establishment

at all times to determine compliance with this Regulation.

 

History Note:        Authority G.S. 130A‑144;

Eff. February 1, 1976;

Readopted Eff. December

5, 1977;

Amended Eff. February

3, 1992.

 

10A NCAC 41A .0303       RECORDING THE SALES OF BIRDS

(a)  A business engaged in the retail sale of birds shall

maintain a record of each sale for at least six months after the sale.  The

record shall include the name and address of the purchaser of each bird.  The

record shall be made available to the Department upon the request of the

Department.

(b)  This Rule shall not apply to the sale of birds for

hunting, scientific, educational, agricultural or food purposes.

 

History Note:        Authority G.S. 130A‑144;

Eff. June 1, 1990.

 

section .0400 - IMMUNIZATION

 

10A NCAC 41A

.0401       DOSAGE AND AGE REQUIREMENTS FOR IMMUNIZATION

(a)  Every individual in North Carolina required to be

immunized pursuant to G.S. 130A-152 through 130A-157 shall be immunized against

the following diseases and have documentation of age-appropriate vaccination in

accordance with the Advisory Committee on Immunization Practices (ACIP).

(1)           Diphtheria, tetanus, and pertussis

(whooping cough) - five doses:  three doses by age seven months; and 2 booster

doses, the first by age 19 months and the second on or after the fourth

birthday and before entering school for the first time.  However:

(A)          Individuals who receive the first booster dose of diphtheria/tetanus/pertussis

vaccine on or after the fourth birthday are not required to have a second

booster.

(B)          Individuals entering college or university for the

first time on or after July 1, 2008 must have had three doses of

tetanus/diphtheria toxoid; one of which must be tetanus/diphtheria/pertussis.

(C)          A booster dose of tetanus/diphtheria/pertussis

vaccine is required for individuals who have not previously received it and are

entering the seventh grade or by 12 years of age, whichever comes first.

(2)           Poliomyelitis vaccine - four doses: two

doses of trivalent type by age five months; a third dose trivalent type before

age 19 months; and a booster dose of trivalent type on or after his or her fourth

birthday and before entering school for the first time.  However:

(A)          An individual attending school who has attained his

or her 18th birthday is not required to receive a polio vaccine.

(B)          The requirements for the booster dose on or after

the fourth birthday do not apply to individuals who began school before July 1,

2015.

(C)          Individuals who receive the third dose of

poliomyelitis vaccine on or after the fourth birthday are not required to

receive a fourth dose if the third dose is given at least six months after the

second dose.

(3)           Measles (rubeola) vaccine - two doses of

live, attenuated vaccine administered at least 28 days apart: the first dose on

or after age 12 months and before age 16 months; and a second dose before entering

school for the first time.  However:

(A)          An individual who has been documented by serological

testing to have a protective antibody titer against measles is not required to

receive measles vaccine.

(B)          An individual who has been diagnosed before January

1, 1994, by a physician (or designee such as a nurse practitioner or physician's

assistant) as having measles (rubeola) disease is not required to receive

measles vaccine.

(C)          An individual born before 1957 is not required to

receive measles vaccine except in measles outbreak situations.

(D)          The requirement for a second dose of measles vaccine

does not apply to individuals who enter school or in college or university for

the first time before July 1, 1994.

(4)           Rubella vaccine - one dose of live,

attenuated vaccine on or after age 12 months and before age 16 months. 

However:

(A)          An individual who has laboratory confirmation of

rubella disease or who has been documented by serological testing to have a

protective antibody titer against rubella is not required to receive rubella vaccine.

(B)          An individual who has attained his or her fiftieth

birthday is not required to receive rubella vaccine except in outbreak situations.

(C)          An individual who entered a college or university

after his or her thirtieth birthday and before February 1, 1989 is not required

to meet the requirement for rubella vaccine except in outbreak situations.

(5)           Mumps vaccine – two doses: the first dose

of live, attenuated vaccine administered on or after age 12 months and before

age 16 months; and a second dose before entering school, college or university

for the first time.  However:

(A)          An individual who has laboratory confirmation of

disease, or has been documented by serological testing to have a protective

antibody titer against mumps is not required to receive the mumps vaccine.

(B)          An individual born before 1957 is not required to

receive the mumps vaccine.

(C)          The requirements for the mumps vaccine do not apply

to individuals who entered the first grade for the first time before July 1,

1987 or college or university before July 1, 1994.

(D)          An individual entering school, college or university

before July 1, 2008 is not required to receive a second dose of mumps vaccine.

(6)           Haemophilus influenzae, b conjugate vaccine

- three doses of HbOC or PRP-T or two doses of PRP-OMP before age 7 months and

a booster dose of any type on or after age 12 months and by age 16 months.  However:

(A)          Individuals who receive the first dose of Haemophilus

influenzae, b vaccine on or after 7 months of age and before 12 months of

age are required to have two doses of HbOC, PRP-T or PRP-OMP and a booster dose

on or after 12 months of age and by age 16 months.

(B)          Individuals who receive the first dose of Haemophilus

influenzae, b vaccine on or after 12 months of age and before 15 months of

age are required to have only 2 doses of HbOC, PRP-T or PRP-OMP and a booster

dose two months later.

(C)          Individuals who receive the first dose of Haemophilus

influenzae, b vaccine on or after 15 months of age are required to have

only one dose of any of the Haemophilus influenzae b conjugate vaccines.

(D)          No individual who has passed his or her fifth

birthday is required to be vaccinated against Haemophilus influenzae, b.

(7)           Hepatitis B vaccine – three doses: the

first dose by age 3 months, a second dose before age 5 months and a third dose

by age 19 months.  However:

(A)          The last dose of the hepatitis B vaccine series

shall not be administered before 24 weeks of age.

(B)          Individuals born before July 1, 1994 are not

required to be vaccinated against hepatitis B.

(8)           Varicella vaccine – two doses administered at

least 28 days apart; one dose on or after age 12 months of age and before age

19 months; and a second dose before entering school for the first time. However:

(A)          An individual who has laboratory confirmation of

varicella disease immunity or has been documented by serological testing to

have a protective antibody titer against varicella is not required to varicella

vaccine.

(B)          An individual who has documentation from a

physician, nurse practitioner, or physician's assistant verifying history of

varicella disease is not required to receive varicella vaccine. The

documentation shall include the name of the individual with a history of

varicella disease, the approximate date or age of infection, and a healthcare

provider signature.

(C)          An individual born before April 1, 2001 is not

required to receive varicella vaccine.

(D)          The requirement for the second dose of varicella

vaccine shall not apply to individuals who enter Kindergarten or first grade for

the first time before July 1, 2015.

(9)           Pneumococcal conjugate vaccine – Four

doses; 3 doses by age 7 months and a booster dose at 12 through 15 months of

age.  However:

(A)          Individuals who receive the first dose of

pneumococcal conjugate vaccine on or after 7 months of age and before 12 months

of age are required to have 2 doses at least 4 weeks apart; and a booster dose

at 12 through 15 months of age.

(B)          Individuals who receive the first dose of

pneumococcal conjugate vaccine on or after 12 months of age and before 24

months of age are required to have 2 doses at least 8 weeks apart to complete

the series.

(C)          Individuals who receive the first dose of

pneumococcal conjugate vaccine on or after 24 months of age and before 5 years

are required to have 1 dose to complete the series.

(D)          No individual who has passed his or her fifth

birthday shall be required to be vaccinated against pneumococcal disease.

(E)           An individual born before July 1, 2015 shall not be

required to receive pneumococcal conjugate vaccine.

(10)         Meningococcal conjugate vaccine – two doses:

one dose is required for individuals entering the seventh grade or by 12 years

of age, whichever comes first, on or after July 1, 2015.  A booster dose is

required by 17 years of age or by entering the 12th grade.  However:

(A)          The first dose does not apply to individuals who

entered seventh grade before July 1, 2015.

(B)          The booster dose does not apply to individuals who

entered the 12th grade before August 1, 2020.

(C)          If the first dose is administered on or after the 16th

birthday, a booster dose is not required.

(D)          An individual born before January 1, 2003 shall not

be required to receive a meningococcal conjugate vaccine.

(b)  The healthcare provider shall administer immunizations

in accordance with this Rule.  However, if a healthcare provider administers

vaccine up to and including the fourth day prior to the required minimum age,

the individual dose is not required to be repeated.  Doses administered more

than four days prior to the requirements are considered invalid doses and shall

be repeated.

(c)  The State Health Director may suspend temporarily any

portion of the requirements of this Rule due to emergency conditions, such as

the unavailability of vaccine.  The Department shall give notice in writing to

all local health departments and other providers currently receiving vaccine

from the Department when the suspension takes effect and when the suspension is

lifted. When any vaccine series is disrupted by such a suspension, the next

dose shall be administered within 90 days of the lifting of the suspension and

the series resumed in accordance with intervals determined by the most recent

recommendations of the Advisory Committee on Immunization Practices. These

recommendations may be accessed free of charge at http://www.cdc.gov/vaccines/acip/.

 

History Note:        Authority G.S. 130A-152(c); 130A-155.1;

Eff. February 1, 1976;

Amended Eff. July 1, 1977;

Readopted Eff. December 5, 1977;

Temporary Amendment Eff. February 1, 1988, for a period

of 180 days to expire on July 29, 1988;

Amended Eff. October 1, 1995; October 1, 1994; January 1,

1994; January 4, 1993;

Temporary Amendment Eff. February 23, 2000; August 20,

1999; May 21, 1999;

Amended Eff. August 1, 2000;

Temporary Amendment Eff. May 17, 2002; April 1, 2002;

February 18, 2002; August 1, 2001;

Amended Eff. July 1, 2015; January 1, 2008; November 1,

2005; January 1, 2005; April 1, 2003.

 

10A NCAC 41A .0402       APPROVED VACCINE PREPARATIONS

All vaccine preparations licensed for interstate use by the

Bureau of Biologic Standards of the U.S. Food and Drug Administration are

approved for use in fulfilling the requirements of 10 NCAC 07A .0401.

 

History Note:        Authority G.S. 130A‑152(c);

Eff. February 1, 1976;

Readopted Eff. December

5, 1977.

 

10A NCAC 41A .0403       NON‑RELIGIOUS PERSONAL BELIEF NO

EXEMPTION

Except as provided in G.S. 130A‑156 and G.S. 130A‑157,

and 10A NCAC 41A .0404 and .0405, no child shall be exempt from the

requirements of 10A NCAC 41 .0401; there is no exception to these requirements

for the case of a personal belief or philosophy of a parent or guardian not

founded upon a religious belief.

 

History Note:        Authority G.S. 130A‑152(c);

Eff. February 1, 1976;

Readopted Eff. December 5, 1977;

Amended Eff. October

1, 1984; July 1, 1979.

 

10A NCAC 41A .0404       MEDICAL EXEMPTIONS FROM IMMUNIZATION

(a)  Certification of a medical exemption by a physician

pursuant to G.S. 130A-156 shall be in writing and shall state the basis of the

exemption, the specific vaccine or vaccines the individual should not receive,

and the length of time the exemption will apply for the individual.

(b)  Medical contraindications for which medical exemptions

may be certified by a physician for immunizations are included in the most

recent General Recommendations of the Advisory Committee on Immunization

Practices, Public Health Services, U.S. Department of Health and Human

Services, published in the Centers for Disease Control and Prevention

publication, the Morbidity and Mortality Weekly Report, which is adopted by

reference including subsequent amendments and additions. A copy is available

for inspection in the Immunization Section at 1330 St. Mary's Street, Raleigh,

North Carolina.  Internet access is available by searching www.cdc.gov/nip. 

 

History Note:        Filed as a Temporary Amendment Eff. February 1, 1988, for a period of 180 days to expire on July

29, 1988;

Authority G.S. 130A‑152(c); 130A‑156;

Eff. July 1, 1979;

Amended Eff. August

1, 2000; January 4, 1993; February 1, 1990; March

1, 1988.

 

10A NCAC 41A .0405       EXEMPTION FOR CLINICAL STUDIES

An individual enrolled in a clinical trial of the efficacy

of a new vaccine preparation or dosage schedule shall be exempted from those

requirements of 10A NCAC 41A .0401 and .0402 which conflict with the trial

protocol.  This exemption shall only apply to individuals who:

(1)           participate in a clinical trial whose protocol is

approved by the State Health Director, and

(2)           fully participate in and complete the clinical

trial.

 

History Note:        Filed as a Temporary Amendment Eff. February 1, 1988, for a period of 180 days to expire on

July 29, 1988;

Authority G.S. 130A‑152(c);

Eff. October 1, 1983;

Amended Eff. March

1, 1988.

 

10A NCAC 41A .0406       ACCESS TO IMMUNIZATION INFORMATION

(a)  Physicians, local health departments and the Department

shall, upon request and without consent release the immunization information

specified in Paragraph (b) of this Rule to the following organizations:

(1)           schools K‑12, whether public, private

or religious;

(2)           licensed and registered childcare

facilities as defined in G.S. 110-86(3) and G.S. 110‑101;

(3)           Head Start;

(4)           colleges and universities, whether public,

private or religious;

(5)           Health Maintenance Organizations; and

(6)           Other state and local health departments

outside of North Carolina.

(b)  The following is the immunization information to be

released to the organizations specified in Paragraph (a) of this Rule:

(1)           name and address;

(2)           name of the parent, guardian, or person

standing in loco parentis;

(3)           date of birth;

(4)           gender;

(5)           race and ethnicity;

(6)           vaccine type, date and dose number administered;

(7)           the name and address of the physician or local

health department that administered each dose; and

(8)           the existence of a medical or religious

exemption determined by the Immunization Section to meet the requirements of

G.S. 130A‑156 and 10A NCAC 41A .0404 or G.S. 130A‑157.  If such a

determination has not been made by the Division of Public Health, the person

shall have access to the certification of medical and religious exemptions

required by G.S. 130A‑156 or G.S. 130A‑157 and 10A NCAC 41A .0404.

 

History Note:        Authority G.S. 130A‑153;

Temporary Adoption Eff. August

9, 1993, for a period of 180 days or until the permanent rule becomes

effective, whichever is sooner;

Eff. January 4, 1994;

Amended Eff. April

1, 2001; August 1, 2000; October 1, 1995.

 

SECTION .0500 ‑ PURCHASE AND DISTRIBUTION OF VACCINE

 

10A NCAC 41A .0501       PURCHASE OF VACCINE

The Division of Public Health may enter into

contracts for the purchase of vaccines.  Any purchase of such vaccines shall be

in accordance with Article 3 of G.S. 143 and 01 NCAC 05A.

 

History Note:        Temporary Rule Eff. October 5, 1986 for a

period of 120 days to expire on February 1, 1987;

Authority S.L. 1986, c. 1008, s. 2;

Eff. February 1, 1987;

Amended Eff. September

1, 1991.

 

10A NCAC 41A .0502       VACCINE FOR PROVIDERS OTHER THAN LOCAL

HEALTH DEPARTMENTS

 

History Note:        Authority G.S. 130A-433;

Temporary Rule Eff. October

5, 1986 for a period of 120 days to expire on February

1, 1987;

Temporary Rule Eff. February

1, 1987 for a period of 120 days to expire on May

31, 1987;

Eff. March 1, 1987;

Temporary Amendment Eff. February

1, 1988, for a period of 180 days to expire on July

29, 1988;

Temporary Amendment Eff. August

26, 1992, for a period 180 days or until the permanent rule becomes effective,

whichever is sooner;

Temporary Amendment Eff. October

1, 1994, for a period of 180 days or until the permanent rule becomes

effective, whichever is sooner;

Amended Eff. October

1, 1995; January 1, 1995; January 4, 1994; January

4, 1993;

Temporary Amendment Eff. December

1, 1998;

Amended Eff. August 1, 2000;

Temporary Amendment Eff. December 1, 2007;

Amended Eff. November 1, 2008;

Repealed Eff. July 1, 2014.

 

SECTION .0600 ‑ SPECIAL PROGRAM/PROJECT FUNDING

 

10A NCAC 41A .0601       RESERVED FOR FUTURE CODIFICATION

 

10A NCAC 41A .0602       PROVIDER ELIGIBILITY

The following organizations are eligible to apply for

special project funds from the Division of Public Health:

(1)           local health departments; and

(2)           Non‑profit or governmental groups such as

public health, educational, and voluntary organizations.

 

History Note:        Authority G.S. 130A‑5(3);

Eff. June 1, 1988.

 

10A NCAC 41A .0603       APPLICATION FOR FUNDS

(a)  Grants for special projects shall be awarded through a

request for proposal (RFP) process that includes notification of all local

health departments of the eligibility criteria, requirements for funding, and

duration of the project period.  This information shall also be available to

other groups or organizations who may wish to apply.  Requests for proposals

may be obtained from the Division of Public Health, 1915 Mail Service

Center, Raleigh, North Carolina 27699-1915.

(b)  The grant proposal shall include the following:

(1)           a project plan which includes an assessment

of the need for the special project, measurable project objectives, and

strategies for meeting the project objectives;

(2)           a proposed budget; and

(3)           an evaluation plan.

(c)  In making the determination of which applications to

approve for funding, each proposal will be judged on its own merits in

competition with all the other proposals submitted to the Section.  Proposals

shall be judged according to the following criteria:

(1)           the proposal demonstrates that a

substantial need exists;

(2)           the proposed project makes a significant

contribution in meeting the established need; and

(3)           the proposed project can be successfully

completed within a reasonable period of time.

(d)  The Division of Epidemiology shall review all grant

proposals submitted on or before the deadline for submission of proposals.  The

Division of Public Health shall approve or deny a grant proposal within 60 days

after the deadline for receipt of the grant proposal.

(e)  A contract shall be signed with each applicant that is

approved for funding.  The number and type of services to be provided under the

contract shall be negotiated with each contractor, approved by the Division of

Public Health, and included as an addendum to the contract. Contracts may be

renewed upon expiration of the contract period when the contractor's proposal

meets the criteria in (c)(1) of this Rule, the contractor has demonstrated

adequate performance, and funds are available.

 

History Note:        Authority G.S. 130A‑5(3);

Eff. June 1, 1988;

Amended Eff. September

1, 1990.

 

10A NCAC 41A .0604       REPORTS

(a)  The contractor shall submit periodic performance

reports as specified in the contract.

(b)  The contractor shall submit a final report at the close

of the contract period.  The report shall include an evaluation addressing progress

in meeting the objectives outlined in the application.

 

History Note:        Authority G.S. 130A‑5(3);

Eff. June 1, 1988.

 

10A NCAC 41A .0605       USE OF SPECIAL PROJECT FUNDS

(a)  Special Project Funds provided pursuant to these Rules

shall be expended solely for the purposes for which the funds were made

available in accordance with the approved application, negotiated project objectives

and budget, the rules in this Section, the terms and conditions of the award,

and the applicable state costs principles.

(b)  A contractor that consistently fails to meet acceptable

levels of performance, as determined through site visits, review of performance

reports, and other appropriate and generally accepted performance standards,

and has been offered consultation and technical assistance, may have special

project funds reduced or discontinued.  Recommendations to reduce or

discontinue funding shall be reviewed and approved by the State Health

Director.

 

History Note:        Authority G.S. 130A‑5(3);

Eff. June 1, 1988.

 

SECTION .0700 - LICENSED NURSING HOME SERVICES

 

10A NCAC 41A .0701       MEDICAL ELIGIBILITY FOR LICENSED NURSING

HOME SERVICES

(a)  A patient shall be medically eligible for reimbursement

for up to 60 days per year, beginning the first day of financial eligibility,

for treatment and convalescence services at a contract nursing home if the

tuberculosis control branch finds that the following criteria are met:

(1)           The applicant must have active pulmonary or

disseminated tuberculosis associated with incapacitation or significant

debilitation which requires a SNF or ICF level of care.  To aid in making this

determination, the referring physician shall provide a treatment plan and

project a length of stay for the patient at the nursing home.

(2)           The applicant must have positive

bacteriology for tuberculosis.  The positive bacteriology (AFB) must have been

obtained within the preceding 14 days.

(3)           The applicant must not be in need of an

acute level of hospital care for any condition.

(4)           The applicant must be 16 years of age or

over.

(5)           The applicant must be referred by a

licensed physician who has first‑hand knowledge of the applicant's mental

and physical condition. The referring physician must furnish a summary of the

applicant's physical and mental condition and known infirmities, and specific

details of treatment and medication the applicant is taking with

recommendations as to dosage, frequency and duration.  This summary must

include all known allergies as well as anti‑tuberculosis and all other

medications that the patient is taking.  In addition, dietary needs, pertinent

x‑rays, and copies of laboratory reports must be forwarded, either with

the patient, if accepted for admission, or in advance.

(6)           The head of the Tuberculosis Control Branch

may make exceptions to the criteria contained in (1) through (5) of this

Paragraph upon a determination that a patient could be best treated for a

tuberculosis condition at a licensed nursing home.

(b)  If the head of the Tuberculosis Control Branch

determines that additional treatment or convalescent care at a licensed nursing

home is medically necessary because of the tuberculosis condition, the head of

the Branch may extend medical eligibility for more than 60 days per year.

(c)  The medical care payments described in this Rule are

available only for services provided at a licensed nursing home which has

contracted with the tuberculosis program for these services.  Further payment

limitations are found in 10A NCAC 45A .0300.

 

History Note:        Authority G.S. 130A‑177;

Eff. October 1, 1985;

Amended Eff. September

1, 1990.

 

SECTION .0800 ‑ COMMUNICABLE DISEASE GRANTS AND

CONTRACTS

 

10A NCAC 41A .0801       COMMUNICABLE DISEASE FINANCIAL GRANTS

AND CONTRACTS

(a)  The Division of Public Health may enter into financial

arrangements with local health departments, community hospitals, nursing homes,

or other convalescent facilities, and with physicians for the purpose of

providing specific health care services for communicable diseases and the

implementation of control measures.

(b)  The Division of Public Health may authorize a local health

department to obtain required diagnostic and treatment services for persons

with syphilis, gonorrhea, chancroid, lymphogranuloma venereum, and granuloma

inguinale from physicians:

(1)           The amount to be charged for these services

shall be negotiated between the local health department and the physician and

approved by the Division of Public Health at the lowest agreeable rate, not to

exceed approved Medicaid reimbursement rates.  Drugs used in treatment may be

provided to such physicians by the local health department.

(2)           The physician shall bill the local health

department for services provided.  The local health department shall submit

requests for payment to the Division of Public Health on forms provided by the

Division of Public Health.

 

History Note:        Authority G. S. 130A‑5; 130A‑135;

130A‑144;

Eff. December 1, 1991;

Amended Eff. April

1, 2003.

 

10A NCAC 41A .0802       RESERVED FOR FUTURE CODIFICATION

 

10A NCAC 41A .0803       RESERVED FOR FUTURE CODIFICATION

 

section .0900 - BIOLOGICAL AGENT REGISTRY

 

10A NCAC 41A .0901       GENERAL

The biological agent registry established by G.S. 130A-149

is administered by the Division of Public Health, 1915 Mail Service

Center, Raleigh, North Carolina 27699-1915.

 

History Note:        Authority G.S. 130A-149;

Temporary Adoption Eff. January

10, 2002;

Eff. April 1, 2003.

 

10A NCAC 41A .0902       BIOLOGICAL AGENTS TO BE REPORTED

The biological agents that shall be reported to the registry

shall be those agents listed as select agents in 42 C.F.R. Part 72, Appendix A

which is adopted herein by reference including subsequent amendments and

editions.  Copies of this federal provision may be inspected at and copies

obtained from the Division of Public Health, 1915 Mail Service Center,

Raleigh, North Carolina 27699-1915 at a cost of ten cents ($.10) per page at

the time of adoption of this Rule.

 

History Note:        Authority G.S. 130A-149;

Temporary Adoption Eff. January

10, 2002;

Eff. April 1, 2003.

 

10A NCAC 41A .0903       WHEN TO REPORT

A person possessing and maintaining a listed biological

agent on the effective date of these Rules shall make a report within 45 days

of the effective date of these Rules.  A person who does not possess and

maintain any listed biological agents on the effective date of these Rules

shall make a report within seven days of receipt of such agents.  A person

shall make an amended report within seven days of any change in the information

contained in the report.  A person shall make a report within 24 hours of any

suspected release, loss or theft of any listed biological agent.

 

History Note:        Authority G.S. 130A-149;

Temporary Adoption Eff. January

10, 2002;

Eff. April 1, 2003.

 

10A NCAC 41A .0904       WHAT TO REPORT

The report shall be made on a form created by the Department

and shall identify the listed biological agents possessed and maintained at the

facility; shall specify the use of the agents for vaccine production, research purposes,

quality control or other use; shall indicate the form of the agents; shall

identify the physical location of the laboratories and the storage areas; and

shall identify the person in charge of the agents.

 

History Note:        Authority G.S. 130A-149;

Temporary Adoption Eff. January

10, 2002;

Eff. April 1, 2003.

 

10A NCAC 41A .0905       EXEMPTION FROM REPORTING

A person who detects a listed biological agent in a clinical

or environmental sample for the purpose of diagnosing disease, epidemiological

surveillance, exposure assessment, reference, verification or proficiency

testing, and who discards the agent within 14 calendar days of receiving notice

of the completion of confirmation testing, or discards the agent within 14

calendar days of using the agent for reference, verification or proficiency

testing, is not required to make a report.

 

History Note:        Authority G.S. 130A-149;

Temporary Adoption Eff. January

10, 2002;

Eff. April 1, 2003.

 

10A NCAC 41A .0906       SECURITY

All persons possessing and maintaining a listed biological

agent must demonstrate compliance with all safeguards contained in the 42

C.F.R. Part 72 and the Rules promulgated thereunder, and must employ those

federal safeguards over the agents they possess and maintain, regardless of

whether the mere possession of the agent is itself required to be registered

under federal law.  The safeguards contained in 42 C.F.R. Part 72 and the Rules

promulgated thereunder are adopted herein by reference including subsequent

amendments and additions. Copies of this federal provision may be inspected at

and copies obtained from the Division of Public Health, 1915 Mail Service

Center, Raleigh, North Carolina 27699-1915, at a cost of ten cents ($.10) per

page at the time of adoption of this Rule.

 

History Note:        Authority G.S. 130A-149;

Temporary Adoption Eff. January

10, 2002;

Eff. April 1, 2003.

 

10A NCAC 41A .0907       RELEASE OF INFORMATION

The Department shall release information contained in the

Biological Agents Registry only by order of the State Health Director upon a

finding that the release is necessary for the conduct of a communicable disease

investigation or for the investigation of a release, theft or loss of a

biological agent.

 

History Note:        Authority G.S. 130A-149;

Temporary Adoption Eff. January

10, 2002;

Eff. April 1, 2003.